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The prostate gland is a male sexual organ, which is situated below the bladder. It is a 
composite organ made up of several glandular and non-glandular components [1]. By 
examining transverse sections o f the prostate the anatomie features can be better 
examined (Figure 1) [2],
Figure 1: Whole mount transverse section o f the prostate with enlarged transition 






















There are three distinct glandular regions each of which arises from a different region 
of the prostatic urethra, therefore the urethra is primarily a point of anatomie 
reference [3], The peripheral zone comprises about 70% of the glandular prostate. 
The Central Zone comprises about 25% of the glandular prostate and the Transition 
Zone about 5% of the glandular tissue [4], but the latter zone can increase 
considerably in volume with advancing age due to benign nodular hyperplasia. 
Peripheral zone tumors are known to be more proliferative and have higher invasive 
potential, they also occur most commonly, comprising 75% of prostate cancers [5, 6]. 
The non-glandular tissues consist of a meshwork of smooth muscle fibers, collagen 
and elastic fibers surrounding and supporting the glandular component throughout the 
prostate gland, as well as some distinct structures such as the pre-prostatic sphincter, 
prostatic sphincter, striated sphincter, anterior fibromuscular stroma, and the nerve 
and vascular supply. Originally a prostatic capsule was described, but this capsule is a
20
discontinuous and rather ill defïned condensation of collagen, which is not well 
delineable, and therefore, the term capsule has been abolished. The prostate produces 
a secretion fluid, which consist of fructose, citrate, prostaglandins, Zn and multiple 
enzymes, which mixes with the seminal fluid and semen at ejaculation. The enzymes 
regulate the viscosity of the ejaculatory fluid, which in turn provide nutrients to the 
sperm and stimulate movement as well as provide protection against infection, and 
protect the sperm from the acidity in the vagina.
Prostate cancer is the foremost diagnosed cancer in males with 29% of all new cancer 
diagnoses being prostate cancer [7], According to the American cancer statistics of 
2012, the mortality of men with prostate cancer is 9% [7]. There is a considerable 
difference between being diagnosed with prostate cancer and eventually dying from 
it, currently most often men who are dying from prostate cancer are elderly men 
whom have “missed” the earlier screening and effective therapy now offered to 
younger patients. Currently when one is diagnosed and treated for prostate cancer in 
the 21st century the likelihood to die from this disease is 3,5% [8]. The overall 
lifetime risk to develop prostate cancer is determined by factors such as age, diet, 
ethnic differences and genetic predisposition, and recently a study by 
Venkatasubramanian et al. found obesity and in particular visceral adipose tissue 
stimulates prostate cancer cell proliferation and angiogenesis [9,10]. The decrease in 
death rates reflect improvements in early detection and treatment [11], As the cure 
rate is highly dependent on the stage of the disease at diagnosis, a priority has been 
set on the early detection of primary prostate cancer and of local recurrence within 10 
years after primary therapy. Some of the screening methods like PSA measurement 
are associated with a high risk o f over diagnosis, but the growing knowledge and 
methods of diagnosing and staging of prostate cancer offer valuable information 
regarding the grade of aggressiveness of this malignancy and the diagnosis thereof 
which then influences the intervention if  any is required [12],
Screening for prostate cancer should be done with care for the reason that at one 
stage or another the need for a biopsy will present itself, should the man not expire 
from some other disease. The American College of Physicians (ACP) recommends 
that clinicians inform men between the age of 50 and 69 years about the limited 
potential benefïts and substantial harms of screening for prostate cancer. It is 
recommended that clinicians base the decision to screen for prostate cancer using the 
prostate-specific antigen (PSA) test on the risk for prostate cancer, a discussion of the 
benefïts and harms of screening, the patient's general health and life expectancy, and 
patiënt preferences. The ACP also recommends that clinicians should not screen for
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prostate cancer using the prostate-specifïc antigen test in patients who do not express 
a clear preference for screening and it is not recoxnmended that clinicians screen for 
prostate cancer using the PSA test in average-risk men under the age of 50 years, men 
over the age o f 69 years, or men with a life expectancy of less than 10 to 15 
years [13].
Prostate cancer screening did not significantly decrease prostate cancer-specific 
mortality in a combined meta-analysis of fïve randomized controlled trials (RCT) - 
The European Randomized Study of Screening for Prostate Cancer (ERSPC); 
Norrkoping; Prostate, Lung Colorectal, and Ovarian (PLCO); Quebec; Stockholm. 
Only the ERSPC reported a 21% significant reduction of prostate cancer-specific 
mortality in a pre-specified subgroup of men aged 55 to 69 years. Pooled data 
currently demonstrates no significant reduction in prostate cancer-specific and overall 
mortality. Any reduction in prostate cancer-specific mortality may take up to 10 years 
to accrue [14]. Overdiagnosis and overtreatment resulting from PSA-based screening 
are common and are associated with treatment-related harms. To avoid overtreatment 
patients with prostate cancer of low volume and low aggressiveness can be offered 
active surveillance [15].
The main diagnostic tools available for diagnosing prostate cancer include 
determining serum concentration of PSA, digital rectal examination and transrectal 
ultrasound guided biopsies [16].
The need for prostate biopsies should be determined on the basis of the PSA level 
and/or a suspicious DRE. The patient’s biological age, potential co-morbidities 
(American Association o f Anesthesiologists Index for co-morbidity (ASA Index) and 
Charlson Co-morbidity Index), and the therapeutic consequences should also be 
considered [17]. Risk stratification is becoming an important tooi to reduce 
unnecessary prostate biopsies. The first elevated PSA level should not prompt an 
immediate biopsy. The PSA level should be verified after a few weeks by the same 
assay under standardized conditions (i.e. no ejaculation and no manipulations, such as 
catheterization, cystoscopy or TUR, and no urinary tract infections) in the same 
diagnostic laboratory, using the same methods [18,19]. It is now considered the 
Standard of care to perform prostate biopsies guided by ultrasound. Although a 
transrectal approach is used for most prostate biopsies, some urologists prefer to use a 
perineal approach. The cancer detection rates of perineal prostate biopsies are 
comparable to those obtained for transrectal biopsies [20,21].
Repeat biopsy should be considered when the following is found:
- rising and/or persistently elevated PSA;
- suspicious DRE;
- atypical small acinar proliferation (ASAP);
- extensive (multiple biopsy sites) prostatic intraepithelial neoplasia (PEN) [22],
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High-grade PIN as an isolated finding is no longer considered an indication for repeat 
biopsy [23]. I f  clinical suspicion for prostate cancer persists in spite of negative 
prostate biopsies, magnetic resonance imaging (MRI) is indicated to investigate the 
possibility of an anterior located prostate cancer, followed by TRUS or MRI-guided 
biopsies of the suspicious area, resulting in an additional prostate cancer detection 
rate of 50% [24].
The incidences of prostate cancer detected by saturation repeat biopsy (> 20 cores) is 
between 30% and 43% and depends on the number of cores sampled during earlier 
biopsies [25], In special situations, saturation biopsy may be performed with the 
transperineal technique. This will detect an additional 38% of prostate cancer.
The biopsies should be reported in consensus with the ISUP 2005 Gleason score [26], 
This involves assigning numbers (called a Gleason pattem or Grade) to cancerous 
prostate tissue, ranging from 1 through 5 based on how the arrangement of cancer 
cells mimic normal prostatic architecture (Fig 2).
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Pattem
1
Circumscribed nodule of closely packed but separate, 




Like pattem 1, fairly circumscribed, yet at the edge of the 
tumor nodule there may be minimal infiltration.
Glands are more loosely arranged and not quite as uniform 
as Gleason pattem 1.
Pattem
3
Discrete glandular units. Typically smaller glands than seen 
in Gleason 1 or 2. Infïltrates in and amongst nonneoplastic 
prostate acini. Marked variation in size and shape. Smoothly 
circumscribed small cribiform nodules of tumor.
Pattem
4
Fused microacinar glands.Ill-defined glands with poorly 
formed glandular lumina. Large cribriform glands. 




Essentially no glandular differentiation composed of solid 
sheets, cords, or single cells.Comedocarcinoma with central 
necrosis surrounded by papillary cribriform, or solid 
masses.
Adapted with permission from dr. Jonathan Epstein.
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When reporting on a needle biopsy the consensus is that the primary pattem and 
highest grade should be recorded i.e. 3 + 5 = 8 (Fig 2). When reporting on radical 
prostatectomy the Gleason score is based on the primary and secondary pattems with 
a comment as to a higher grade tertiary pattem because this is of prognostic 
relevance [26].
There is some evidence that zonal location of prostate cancer is of prognostic 
relevance. Although the majority of prostate cancer arises in the peripheral zone 
(75%), many prostates also harbor separate tumor foei in the transition zone, and 
some cancers are exclusively located in that zone [27]. Prostate specific antigen 
(PSA) serum level, Gleason score and stage are the most important markers for 
prognosis.
Microvessel density has also been identifïed as a possible prognostic marker but 
needs further well designed studies to establish the best assay method and 
interpretation criteria [28]. The underlying principle for counting microvessels in 
tumor is that these vessels originated from tumor cell clones with the highest 
angiogenic potential and consequently with the easiest access to the blood circulation 
and with an increased propensity o f producing metastasis capable o f becoming 
angiogenic and growing tumors. Angiogenesis is the development of new branching 
vessels from existing vasculature. Although angiogenesis is a hallmark of cancer it is 
also a normal physiological process. Tumor growth is dependent on adjacent 
supportive host tissue especially new blood vessels which has to form around the 
tumor [29], Angiogenesis allows increased exchange of oxygen, nutrients and waste 
products for the crowded cell population for which the current vessels do not sufïïce. 
Several investigators have found increased microvessel density (MVD) in prostate 
cancer compared to normal prostate tissue [30, 31-33], Other researchers could not 
prove an increase in MVD in prostate cancer compared to normal prostate tissue [34]. 
These differences may be due to tumor heterogeneity, differences in subjective 
assessment or the use of different antibody and iimnunohistochemical techniques. 
Multiple previous reports examining MVD using various antibodies and counting 
methods indicate that even if  univariate analysis o f MVD values did show correlation 
with some prostate cancer parameters, MVD counts fail on multivariate analysis as an 
independent prognostic factor [35-38], Moreover, the predictive accuracy of the 
multivariable base model including age, PSA, stage, Gleason score, and margin status 
was not meaningfully improved by the addition of MVD [39].
Accurate quantifïcation of microvasculature is important to investigate the 
contribution of MVD in Dynamic Contrast Enhanced Imaging methods. The MVD 
quantifïcation method should be 1) accurate, 2) it should be applicable to all kinds of
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tissue, 3) it should be objective, 4) and it should be reproducible. The most commonly 
used methods for vessel quantifïcation are the Chalkey method, Microvessel Density 
method (Weidner method), semi-automated quantifïcation method based on region of 
interest selection and fully automated counting. In this thesis an in house developed 
computer controlled automated quantifïcation method with a motorized scanning 
stage was used (Chapter 2).
The Microvessel density method or (Weidner method) consists of choosing a 
“hotspot” region of perceived increased vascularity. The area of tumour that contains 
the maximum number of discrete microvessels to be counted is identifïed by scanning 
the entire tumour at low power (x40 and xlOO). The number of highlighted vessels is 
then counted in the selected region under high magnifïcation (x250 -  x400) [40], A 
countable vessel is identifïed as separate from adjacent microvessels, tumour cells or 
connective tissue elements. Those, which appear to be derived from the same vessel if 
separate, are also counted. Vessel lumens and erythrocytes are not included in the 
criteria for defining microvessels. The Chalkey method consists of selecting a hotspot 
and then using a 25 dot Chalkey microscope eyepiece graticule to quantify tumour 
microvessels at power x250 (grid area 0.196mm2) [40]. This gives a measure of the 
relative area that the vessels cover rather than microvessel density, but there is a 
strong significant association between vessel area and number [41].
The reproducibility of the Chalkey and Weidner methods are poor due to the 
subjective nature by which hotspots are selected. It has been demonstrated that 
observer experience determines the success of identifying the relevant hot spot, and 
for both methods a high degree of operator instruction and experience is required 
[40]. When using the Chalkey method it has been shown the intra-hot-spot 
heterogeneity is not negligible and influences the MVD estimation. Compared to the 
Weidner method the Chalkey method is preferred because it is faster and more 
reproducible [42], Although semi-automated and fully automated quantifïcation has 
several disadvantages, such as high cost, optimal staining requirements, suboptimal 
algorithm design, fine-tuning or threshold settings and expensive motorized scanning 
stages, it is superior to manual counting in that there is greater objectivity, greater 
accuracy and better reproducibility. Several additional vessel parameters can be 
measured like microvessel parameter and microvessel area for further objectification 
of microvessels [34, 43], Automated counting of microvessels is preferable to manual 
counting because of the reduction in measurement time, the complete scanning of the 
tumor, the greater accuracy and objectivity and the possibility of visual inspection and 
relocation of each measurement field afterwards [44].
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Woven like a mesh between the blood vessels we fïnd the lymph vessels. The 
difference in function and architecture between lymph and blood vessels make it 
essential to distinguish between the two vascular systems if accurate research is 
required. Lymphatic’s play an important role in tissue fluid homeostasis, and 
transport other substances including cells, which leaked from the vascular system, and 
cells shed into the lymphatic vasculature from the tissue is also transported by the 
lymphatic’s (metastasis). The lymphatic vasculature has not received as much 
scientific attention as the blood vasculature due to the lack of lymphatic specific 
markers. In the last decennium, however, researchers have been able to identify 
lymph vessels by means of lymphatic specifïc antibodies (Podoplanin, D2-40, LYVE- 
1).
It has been found that lymphatic vessels in tumor are rendered non functional by 
tumor over growth rather than lymph angiogenesis [45]. Intratumoral lymph vessels 
are non-functional while lymphatic’s in tumor margin are sufficiënt for metastasis[46, 
47]. Peritumoral lymph vessel density and peritumoral lymphatic invasion are 
important predictors for lymph node metastasis in prostate cancer [48].
Transition zone tumors consists of 20-25% of prostate cancers and these include 
transition zone cancer and cancer of the anteriofibromuscular stroma area [1, 49, 50], 
Diagnosing these tumors are challenging due to their anterior location and most 
transition zone tumors are not palpable by rectal examination and not visible by 
transrectal ultrasound and less often detected by Standard biopsy schemes because 
they occur frequently beyond the posterior tranrectal biopsy schemes. Increasing PSA 
with repetitive negative biopsy series is often the only indicator for transition zone 
carcinoma. Transition zone cancers are considered less aggressive than peripheral 
zone cancers but it remains arguable whether the clinicopathological differences can 
be explained by anatomical location alone or also by intrinsic biological differences 
as well. Only one study compared microvascularity in transition zone tumors vs. 
peripheral zone tumors and found a significant lower mean microvessel density in 
transition zone tumors than in peripheral zone tumors but the results were not 
compared to normal tissue [29]. Chapter 4 of this thesis represents the fïrst study to 
compare normal transition zone with transition zone tumor.
A variety of antibodies have been used in staining for MVD including factor VIII- 
related antigen (vWF), CD31 and CD34 [51, 52]. Staining with the chosen antibodies 
proved to be successfïil. CD34 is a myeloid progenitor cell antigen and is frequently 
detected on a variety of mesenchymal, inflammatory cells and lymphatic vessels; this 
compromises the specificity of CD34 as a marker for vascularity which may 
contribute to falsely elevated microvessel density values [53-56]. CD31 showed
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almost complete specifïcity and sensitivity for microvessels and has complete 
specifïcity for endothelium, only rarely staining inflammatory cells.
There are also a variety of lymphatic specifïc antibodies like Podoplanin, D2-40 
and LYVE-1; there is little reason to prefer any of these. D2-40 was used to identify 
lymphatics and proved sensitive and specifïc for lymphatics and completely fulfilled 
our needs required for staining purposes [57].
The in vivo visualization of prostate cancer is continuously improving as a result of 
new developments in imaging techniques (DWI-MRI, Spectroscopy, FDG 
PET/CT [58]) and the use of contrast agents. The contrast enhancement on MRI 
reflects hemodynamic changes in the prostate providing fimctional rather than 
anatomical data. Close comparison with detailed histopathology results can contribute 
to understanding the physiological principles underlying dynamic contrast enhanced 
magnetic resonance imaging (DCE-MRI). Insight into the characteristics of the 
vascularity of normal prostate and prostate cancer and inter-patient variation will 
increase the understanding of dynamic contrast enhanced magnetic resonance 
imaging (DCE-MRI). Increased microvessel density (MVD), microvessel area 
(MVA) and microvessel perimeter (MVP) in prostate tumor tissue compared to 
normal tissue has been established [30, 31-33], The possibility of evaluating 
enhancement kinetics like the transfer constant (K*1™8), rate constant (KeP) and 
extravascular extracellular volume (Ve) from DCE-MRI in prostate tissue, then 
comparing it to MVD, MVA and MVP is a promising tooi in the management of 
prostate cancer as it allows mapping of the area with increased vascular parameters 
and permeability associated with tumor growth. Literature data have demonstrated 
that the addition to DCE-MRI to morphological imaging based on T2-weighted 
sequences improves accuracy in prostate cancer staging, in particular equivocal cases 
of extra prostatic extension and seminal vesicle invasion [59]. More recently, it has 
been reported that in individual cases, the peak enhancement measured in voxels in 
neoplastic tissue was substantially higher than the normal peripheral and transition 
zone[60], Quantitative analysis from DCE-MRI demonstrates prostate cancer has 
significant different enhancement pattems from normal tissue, thus it can be 
hypothesized that the differences depend on the increased microvascular density and 
leakiness associated with tumor neoangiogenesis [61,62], Providing the potential to 
evaluate tumor neovascularisation with DCE-MRI, this could lead to better localizing 
of the tumor and would negate the need for extensive biopsy samples and focus the 
attention of clinicians on clinically relevant prostatic tumors.
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This thesis was specifically aimed at measuring MVD, MVA and MVP in different 
zones of the prostate and fïnding anomalies and comparisons, which can explain the 
images found when scanning the prostate with DCE-MRI and to prove the clinical 
validity of DCE-MRI. We do this in order to bring about in the clinic a tooi, which 
can be used to steer clear of extensive invasive sampling but deliver an accurate 
diagnosis.
Scope o f the Thesis:
This thesis was specifically aimed at measuring microvessels and their parameters; 
microvessel density (MVD), microvessel area (MVA) and microvessel perimeter 
(MVP) in prostate cancer and the contra lateral normal prostate tissue of different 
zones of the prostate and finding anomalies and comparisons. These were correlated 
with the images found when scanning the prostate with DCE-MRI and the chosen 
pharmacokinetic parameters; rate constant (KeP), transfer constant (Ktrans) and 
extravascular extracellular volume (Ve). We do this in order to validate images found 
on DCE-MRI through angiogenesis, so ultimately extensive invasive sampling will 
not be necessary.
In chapter 2 the application of a repeatable computerized whole slide quantification 
method show increased vascular parameters in pT2 prostate cancer as compared to 
normal prostate tissue. This can be used as a tooi when researching the vascular 
parameters of prostate tissue in histopathological cut sections.
Prostate cancer has been considered to disseminate initially and primarily into the 
lymphatic system [63], lymph node metastasis is one of the strongest predictors of 
poor prognosis in patients with prostate cancer [64, 65], The characteristics of the 
lymphatic system in prostate cancer have not been described in detail previously. In 
chapter 3 an interactive and automated method was applied to quantify lymphatic 
parameters and morphology. Significant differences between lymphatic vessel 
perimeter and area from tumor tissue as compared to lymphatic vasculature in normal 
prostate tissue is shown. It is revealed that there is no increase in density but in area 
and perimeter of lymphatics in the tumor. The limited literature on this subject 
provides a unified stance, describing non-functional lymphatics within the tumor and 
functional lymphatics peritumoral which serve as major conduits for 
metastasis [48,66],
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In chapter 4 comparisons was drawn between transition zone tumors, normal 
transition zone, peripheral zone tissue and benign nodular hyperplasia (BPH), so 
insight could be gained from potential differences in microvascularity in these areas, 
which could contribute in understanding the results from DCE-MRI. Characteristics 
of microvasculature did not deviate signifïcantly between transition zone tumor and 
normal transition zone o f the prostate.
In chapter 5 we aim to compare the histological parameters of microvascularity with 
the pharmacokinetic enhancement (PK) parameters of DCE-MRI to obtain better 
insight in the extent to which histological microvascular parameters contribute to the 
enhancement of DCE-MRI. This is important to determine the potential o f DCE-MRI 
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Background Contrast enhanced imaging enables powerful, non-invasive diagnostics, 
important for detection and staging o f early prostate cancer. The uptake of contrast 
agent is increased in prostate cancer as compared to normal prostate tissue. To reveal 
the underlying physiological mechanisms, quantifïcation of tissue components in 
pathology specimens may yield important information. Aim of this study was to 
investigate whether microvascularity is increased in prostate confïned cancer (pT2).
Methods Radical prostatectomy specimens o f 26 patients were selected for organ 
confïned peripheral zone tumours which were restricted to one side of the prostate. 
Microvessels were visualized by immunohistochemistry against CD31. Specimens 
were scanned using a computer controlled microscope and scanning stage and vessels 
were recognized automatically. Pseudocolour mappings were produced showing 
number of vascular profïles (MVD), vascular area (MVA) and perimeter (MVP) in an 
overview of the entire prostate transection. MVD is a common measure for 
vascularity, whereas MVA represents the 3D vascular volume and MVP the perfused 
surface area. Mean, coëfficiënt of variation and 75th percentile of these parameters 
were calculated automatically in manually indicated areas, consisting of the entire 
tumour area and the corresponding normal area in the contra lateral side of the 
prostate.
Results The mappings clearly indicate areas of increased vascularity in prostate 
transections. In tumour tissue an increase was found compared to normal tissue of 
81%, 49% and 62% for mean MVD, mean MVA and mean MVP, respectively 
(p<0.001 for all comparisons). In contrast, the heterogeneity in tumour vasculature 
was signifïcantly decreased as compared to normal prostate (p<0.001).
Conclusions Characteristics of microvasculature deviated signifïcantly in pT2 
prostate tumour as compared to normal tissue.
Key words: prostate cancer, microvasculature, digital image analysis, quantifïcation, 
whole slide scanning.
Introduction
Prostate cancer is the most frequently diagnosed cancer among men and the second 
highest cause of cancer related death[l], In the last decades, introduction of PSA 
screening has resulted in earlier detection of prostate cancer, leading to a continued 
slight decline in mortality [1], The in vivo visualization of prostate cancer is
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continuously improving as a result of new developments in imaging techniques (MRI, 
ultrasound) and the use of contrast agents. The contrast enhancement in these imaging 
modalities reflects hemodynamic changes in the prostate, providing functional rather 
than anatomical data. Close comparison with detailed histopathology results has 
contributed to the understanding of MRI data. Unfortunately, the detection of small 
tumours remains an important challenge to the urologist and radiologist. Insight in the 
characteristics of the microvascularity of normal prostate and prostate cancer will 
increase the understanding o f contrast-enhanced radiologie imaging.
Microvascularity may be assessed quantitatively, for instance by counting the 
number of vascular profiles (microvascular density, MVD) in an 
immunohistochemically stained tissue section. MVD is considered an important 
marker for neo-angiogenesis which in turn is responsible for local growth and 
metastasis in tumours [2], Compared to normal tissue, increased MVD has been 
shown in primary tumour and metastases of melanoma [3], breast cancer [4], cervical 
cancer [5], stomach cancer [6], lung cancer [7] as well as prostate cancer [8, 9]. In 
prostate cancer MVD has been reported to be associated with Gleason score, stage 
and tumour progression, although somewhat contradictory results were found [10-14], 
In general, contradictory results may be attributed to differences in either the 
composition of the patiënt group or because of differences in the quantification 
procedure. Parameters that influence the outcome of the counting procedure include 
the choice of antibody used to highlight vascular profiles, the method of selection of 
the area to be measured and the actual counting method.
In prostate specimens, the widely used CD34 monoclonal antibody (MAb) is less 
optimal for microvessel staining, because of abundant stromal staining. CD31 MAb is 
preferred over anti-von Willebrand factor, because of stronger staining of the vascular 
endothelium [15]. In many published studies, the actual counting of vascular profiles 
is performed manually, applying the so called Weidner procedure [16], Using this 
procedure, microvascular profiles are counted in visually indentifïed ‘vascular hot 
spots’. It was shown that especially localizing these hot spots is prone to observer 
bias, limiting the applicability of such procedures [17, 18], Use of a Chalkey counting 
grid was recommended to improve reproducibility [18], Because the grid is applied to 
visually identified hot spots as well, the main source of variability is not reduced with 
this method. Application of digital image analysis has been shown to enhance 
reproducibility of both selection of the measurement area and of the actual counting 
of vascular profiles [17, 19], Moreover, digital image analysis may yield additional 
information describing the geometry of vascular profiles (e.g. vascular area and 
perimeter).
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The aim of the present study was to investigate differences in microvascular 
characteristics between pT2 prostate tumours and normal prostate tissue. An 
optimized quantifïcation technique was applied, which tries to avoid the deficiencies 
that lead to ambiguities, by selecting an optimal staining technique combined with 
computerized quantifïcation. Characteristics of the microvasculature in unilateral 
peripheral zone pT2 tumours were compared with the corresponding contra lateral 
normal peripheral zone. Digital image analysis was used to construct spatial 
mappings for three parameters, microvessel density (MVD), vascular area (MVA) 
and vascular perimeter (MVP), in a whole transverse section of the prostate. These 
mappings were used to construct pseudocolour overviews of vascular parameters. 
Also, vascular parameters could be assessed objectively in tumour and normal tissue, 
avoiding subjective hot spot selection.
Methods
Patiënt selection and pathology
To decrease inter-tumour variability, this study was restricted to peripheral zone 
tumours, which constitute 80% of prostate cancer and are known to be more 
proliferative and have higher invasive potential as compared to transition zone 
tumours [20]. Twenty-six radical prostatectomy specimens with unilateral peripheral 
zone pT2 tumours were included in this study. All patients showed negative resection 
margins and did not receive neo-adjuvant therapy. The serum PSA level and patiënt 
age at time of radical prostatectomy were obtained from case history.
All Prostatectomy specimens had been completely embedded, as described 
previously [21], In summary, specimens were cut into serial 4mm transverse slices 
perpendicular to the dorsal rectal surface. The slices were photographed with a CCD- 
camera. Apical and basal slices were then sectioned parasagitally. Depending on the 
size of the prostate, the remaining slices were divided in two or four parts in order to 
fit routine cassettes. The tumour margins were marked on haematoxylin and eosin 
(H&E) stained sections by an experienced uropathologist (CAHK). Tumour was then 
outlined on the macroscopic photographs in order to reconstruct tumour extension and 
multifocality. For this study, also, a mirror image of equal size compared to the 
tumour was marked in the contra lateral normal peripheral zone tissue. Mild to 
moderate chronic inflammation and various subtypes of atrophy were accepted as 
“normal” variations because of their high frequency of occurrence in prostates at the 
age at which adenocarcinoma occurs. Severe and extensive inflammation and 
multifocal high grade PIN, however, were regarded as abnormal. The Gleason grade
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and score were determined using the 2005 ISUP Modifïed Gleason System [22]. 
Tumour volume was determined by measuring the largest tumour diameter and the 
diameter perpendicular to the largest diameter in all tissue sections containing 
tumour. Section tumour area was calculated from these diameters by assuming 
elliptical tumour shape, was integrated over all sections and multiplied by the section 
thickness to arrive at the estimated tumour volume.
Immunohistochemistry
CD31 immunohistochemistry was performed on sections serial to the H&E stained 
sections containing marked regions. Tissue sections of 4 (jm were deparaffïnised, 
rehydrated and pre-treated using an EDTA antigen retrieval system. Endogenous 
peroxidase activity was blocked by using 3% H2O2 in methanol for 10 minutes. Next, 
specimens were rinsed with water and phosphate buffered saline (PBS). A mouse 
anti-human CD31 monoclonal antibody (Clone JC70A, DakoCytomation, 
Copenhagen, Denmark) was used as the primary antibody at a dilution of 1:10. The 
specimens were incubated ovemight at 4°C. Specimens were washed in PBS and 
incubated with PowerVision (Poly-Hrp-Anti Ms/Rb/Rt IgG Biotin-free, 
Immunologie, The Netherlands) for 30 minutes. Specimens were washed in PBS for 
10 minutes and subsequently incubated with Power-DAB (Immunologie, The 
Netherlands) for 5 minutes resulting in brown staining of vascular endothelium. 
Finally, specimens were washed in water, dehydrated and mounted with Quick-D 
(Klinipath, The Netherlands). Sections used for quantitative analysis were not 
counterstained.
Automated analysis of microvasculature
To allow analysis of the spatial distribution of vessel characteristics, a mapping 
technique was developed based on a previously described scanning system [23]. 
Sections were scanned exhaustively using an AxioCam MRc (Carl Zeiss, Germany) 
connected to an AxioPlan 2 Imaging microscope (Carl Zeiss, Germany). The 
microscope was equipped with a computer controlled scanning stage (8 specimen 
stage, Marzhauser GmbH, Wetzlar, Germany controlled by a Ludl MAC5000 
controller, Ludl Electronic Products Ltd., Hawthome, NY). Images were acquired 
using a lOx objective (Plan Apochromat, NA=0.32), resulting in a specimen level 
pixel size of 1.06x1,06(xm2. All image acquisition and processing were performed 
using custom written macros in KS400 image analysis software (version 3.0, Carl 
Zeiss, Germany). Each microscopie field of vision was focused automatically before 
acquisition. Images o f consecutive individual microscopie fïelds were automatically 
acquired and stitched together into large 24 bit RGB TIFF images. Recognition of
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vascular profïles was performed based on the RGB colour image data. Resulting 
binary images were sampled down by a factor 2 and the result of automated vessel 
recognition was shown on the computer monitor. Subsequent interactive correction 
was limited to removal o f falsely recognized non-vascular objects and drawing of 
vascular profïles not recognized by the automated procedure. Mapping of MVD, 
microvascular area (MVA) and perimeter (MVP) was performed by calculating these 
parameters (cumulative) in a small circular neighbourhood around each pixel of the 
mapping and assigning a pseudocolour to the pixel expressing these parameter values. 
Properly assessed in 2D sections, MVD may be regarded as a measure of length 
density per volume unit, MVA as a volume per volume measure and MVP as a 
surface area per volume measure [24], Especially MVP may be of interest, as this 
measure represents the (relative) available vascular diffusion surface. Mappings were 
produced for a local neighbourhood with radius 235 (jm (area= 0.173 mm2, 
corresponding to one single microscopie fields using a 20x objective). A transverse 
section through the entire prostate consisted of two to four Standard histological 
sections. Images o f the sections comprising a complete transverse section of the 
prostate were included in a single mapping (see e.g. Figure la  and b).
In addition to the production of these pseudocolor mappings, quantitative data were 
extracted from scanned specimens in manually delineated regions comprising the 
tumour and contra lateral normal tissue. To reduce the effect of region size, the region 
in normal prostate tissue was drawn with size and shape comparable to the tumour 
area. For MVD, MVA and MVP the mean value, coëfficiënt of variation (CV) and 
75th percentile were calculated for each prostate over these two regions. The 75* 
percentile gives information on the higher vascularised areas and is therefore better 
comparable to the hot spot MVD than the mean MVD. The CV, defined as 100% * 
Standard deviation / mean value, is a useful tooi to compare variability between 
populations independent of their respective means [25],
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Figure 1: Pseudocolor mappings fo r  two prostate transections (A, B and E, F) 
containing peripheral zone pT2 tumour, as well as corresponding CD31-stained 
histological images (lOOx magnification; C,D and G, H). Different regions are 
indicated by: T — tumour region, N  — normal region; U -  Urethra. Shown are 
microvessel density (MVD) and microvessel perimeter (MVP).
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Because a number o f vascular parameters showed a distribution which deviated 
signifïcantly from normal (p<0.05), non-parametric statistics were used throughout 
this study. To compare data from tumour and normal tissue pair-wise, Wilcoxon 
signed ranks test was used. Spearman correlation analysis was applied to study 
correlation between vascular parameters and patiënt age and tumour characteristics 
(Gleason grade and score, serum PSA level, tumour volume). All probabilities from 
statistical tests are based on two-sided testing, signifïcance being defined as p<0.05. 
All statistics were performed using SPSS software (SPSS Inc, Chicago, II, USA).
Results
Characteristics of the microvasculature could be quantified successfully in all 26 
radical prostatectomy specimens. Mean patiënt age was 60.4 years (range 47 -  70 
years) with mean preoperative PSA of 6.43 ng/1 (range: 2.33 -  12.1 ng/1). Tumours 
were generally small with a volume ranging from 0.3 -  4.8 cm3 (mean 1.56 cm3). The 
Gleason grade ranged from 2 - 5  (mean 3.33) with mean Gleason score 6.5 (range 5 -  
9). Immunohistochemical staining of microvessels using the CD31 MAb resulted in 
specific, easily identifiable vascular profiles (Figure 1 C,D,G,H). Automated 
recognition o f vascular profiles was generally of high quality, requiring only a 
minimum of interactive correction.
In general, pseudocolor mappings provided a distinct overview of the spatial 
distribution of microvascular characteristics. Figure 1 shows examples of mappings 
for two cases. The fïrst example case clearly shows enhanced MVD (Figure IA) and 
MVP (Figure 1B) in tumour compared to normal tissue. Inspection of the CD31 
stained histological sections confirms this observation, showing an increased number 
of vascular profiles in the tumour (Figure 1C,D). In the second example case (Figure 
1E-H), a similar increase was seen, be it less pronounced (especially regarding MVP).
Tables I -  III show results for the quantitative data derived from mappings, 
averaged over all patients. Figure 2 shows the 10-based logarithm of the ratio 
between tumour and normal tissue for these parameters. A value of 0 indicates no 
difference and values > 0 indicate increased values in tumour tissue. In the majority 
of cases, mean and 75* percentile of MVD and MVP and to a lesser extent MVA 
were increased in tumour as compared to normal tissue. Mean MVD, MVA and MVP 
showed a mean increase of 81%, 49% and 62%, respectively. Increase in the 75th 
percentile was less pronounced (70%, 51% and 55% for MVD, MVA and MVP, 
respectively). All differences were statistically significant (p<0.001). In contrast, the
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heterogeneity of the vasculature, expressed in the CV, was found decreased in tumour 
as compared to normal tissue for all parameters (p<0.001).
Table 1: Microvessel density (MVD), averaged over 26patients.
MVD
Mean (1/mm2) Coeff. of variation (%) 75th percentile (1/mm2)
Normal Tumour Ratio Normal Tumour Ratio Normal Tumour Ratio
Mean 81.9 125.5 1.81 55.8 43.6 082 109.5 161.8 1.70
Stddev 34.5 38.0 0.97 16.9 926 0.19 44.0 47.7 0.82
Range
2 7 .9 -
147.8
4 8 .3 -
238.2
0 .8 0 -
5.10
33 9 -  
112.1
30 9 -  
71.9
0 4 3 -  
1.16
3 7 .3 -
198.9
6 7 .1 -
313.2
0 .7 6 -
4.45
p<0.001 p<0 001 p<0.001
Coëfficiënt of variation defined as 100% * Standard deviation / mean. Ratio is the 
ratio between data from tumour and normal tissue. Statistical results (p-values) from 
Wilcoxon signed ranks test.
Table 2: Microvascular area (MVA), averaged over 26patients
MVA
Mean (%) Coeff. of variation (%) 75th percentile (%)
Normal Tumour Ratio Normal Tumour Ratio Normal Tumour Ratio
Mean 1.97 2.72 1.49 103.8 829 083 2.50 3.49 1.51
Stddev 0.84 1.67 0.75 35.2 255 0.20 1.17 2.25 0.71
Range




0 .7 8 -
3.86
6 2 .4 -
238.6
5 3 .6 -
163.8
0 4 5 -
1 31
0 .5 5 -
5.33
1.65 -  
12.1
0 .7 4 -
3.58
p<0.001 p<0.001 p<0.001
Coëfficiënt of variation defined as 100% * Standard deviation / mean. Ratio is the 
ratio between data from tumour and normal tissue. Statistical results (p-values) from 
Wilcoxon signed ranks test.
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Table 3: Microvascular perimeter (MVP), averagedover 26 patients.
MVP
Mean (mm/mm2) Coeff. of variation (%) 7SUl percentile (mm/mm2)
Normal Tumour Ratio Normal Tumour Ratio Normal Tumour Ratio
Mean 5.50 8.17 1.62 64.2 487 0 81 7.44 10.6 1.55
Stddev 2.27 3.16 0.62 22 5 102 0 19 2.95 4.08 0.58
Range
1 .7 5 -
8.76




4 3 .2 -
132.9
36 2 -  
77.9
0 4 4 -
1 13
2 .4 3 -
11.8
5 .8 2 -
21.8
0 .9 2 -
3.27
pO.OOl p<0.001 p<0.001
Coëfficiënt o f variation defined as 100% * Standard deviation / mean. Ratio is the 
ratio between data from tumour and normal tissue. Statistical results (p-values) from 
Wilcoxon signed ranks test.
Figure 2: Logarithm o f  ratio between parameters (mean, coëfficiënt o f  variation and 
75,h percentile) calculated over the tumour area and corresponding contra lateral 
normal prostate tissue. A value o f  0 indicates no difference, with log ratio>0 
indicating an increased value in the tumour. Shown are microvessel density (MVD), 
microvascular area (MVA) and microvascular perimeter (MVP). Each patiënt is 
represented by an asterisk (n=26).
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In the area used as reference normal peripheral zone tissue, mild to moderate 
inflammation was present in 16 out of the 26 cases. Simple atrophy and focal atrophy 
with cysts (according to the recent Working Group Classification) [26] were focally 
present in 18 and 7 cases, respectively. Postatrophic hyperplasia and an incidental 
gland with HGPIN were present in only one case each. In none of the cases extensive 
HGPIN or severe inflammation was present in the area used as normal reference 
control tissue. No significant differences were observed in vascular parameters 
(MVD, MVA, MVP) between cases with inflammation and/or atrophy compared to 
cases without inflammation and/or atrophy in the normal tissue.
No correlation was found between patiënt age or tumour characteristics (PSA, 
volume, Gleason grade and score) and vascular parameters (MVD, MVA, MVP). A 
significant age -  volume correlation was found (r=0.49, p=0.012).
Discussion
In this study, a consistent significant increase in vascular parameters MVD, MVA and 
MVP was found in tumour versus normal prostate. This is in concordance with 
previous studies [8, 9, 27, 28], Bigler et al found on average a two-fold increase in 
MVD in 15 cases of prostate cancer compared to normal prostate tissue. MVD was 
averaged over 5 randomly selected regions. Kaygusuz et al also found a two-fold 
increase in MVD, measured as the mean of three hot spots. This figure is slightly 
higher than the 1.8-fold increase (1.7-fold for 75* percentile) found in the present 
study. Bigler et al studied in general larger tumours with a higher stage (50% > pT3) 
compared to the present study. Kaygusuz compared between tumour and benign 
hyperplasia, which may exhibit microvascular properties differing from those in 
normal peripheral zone. The present study is focused on small (pT2) tumours, as these 
are most difficult to visualize in vivo. In contrast, only a 1.47-fold increase was found 
for MVD assessed in hot spots in the study o f Eberhard et al [28], which is markedly 
smaller than the 1.7-fold increase observed in the present study. Eberhard does not 
give information about tumour volume, stage or zonal origin o f normal tissue.
Chalkey point counting showed a 2.4-fold increase in vascularity for pT2 
tumours compared to normal prostate [8], The Chalkey procedure yields information 
regarding the area o f vascular profiles [24], comparable to the MVA in the present 
study. Results of the present study show only a 1.5-fold increase in tumour for the 
75th percentile o f MVA. This difference may be explained by the way the Chalkey 
procedure is carried out. The Chalkey procedure is most often applied as described by
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Fox [18], in which the graticule is rotated to obtain a maximum number of hits. 
However, this is not in agreement with the original publication by Chalkey, in which 
the grid is placed at random over the structures of interest [29, 30]. Both MVD 
quantifïcation according to Weidner and the Chalkey procedure as described by Fox 
do not fully satisfy the basic concepts of stereology [30] and therefore may lead to 
biased results [31, 32].
In a study comparing MVD assessed according to Weidner [16] and Chalkey 
point counting it was concluded that in general the two methods show only moderate 
correlation [30], It was also shown that for a number of tumour types (e.g. prostate) 
only MVD correlated with prognosis, whereas for other tumours the Chalkey count 
exhibited more clinically relevant information. This underlines our vision that 
different parameters may yield complementary information, and should ideally be 
assessed simultaneously [33], The use of digital image analysis is therefore 
recommended [34]. MVD might not be the most important vascular parameter [18]. 
In the present study, especially the increase in MVP, which may be regarded as a 
relative measure for the 3D vascular difïusion surface, may contribute to increased 
uptake of radiological contrast agents in prostate cancer as compared to normal 
prostate tissue.
Both the method according to Weidner and the Chalkey technique as proposed by 
Fox assess vascular parameters in so-called vascular hot spots, which are considered 
of highest biological relevance [18]. It has been shown that identifïcation of the hot 
spot is subject to observer bias and is poorly reproducible [17, 35], It has also been 
shown that hot spot selection may be performed objectively by exhaustive sampling 
of a specimen using digital image analysis [17, 19]. However, as the variation 
between sections from a single tissue block and between tissue blocks is 
considerable [36], the value of locating a single hot spot in a section remains 
doubtful. Reproducibility may be increased by averaging over a number of highly 
vascularised areas [37]. In the present study, both the mean value and the 75* 
percentile over the entire tumour area and contra lateral normal tissue were 
calculated, to achieve a compromise between reproducibility and assessment of the 
most relevant information. As discussed above, the 75th percentile provides 
information on the higher vascularised areas and is therefore better comparable to the 
hot spot than the mean value.
The heterogeneity, expressed in the CV of vascular parameters MVD, MVA and 
MVP was decreased in tumour as compared to normal tissue in the present study. The 
same observation may be derived from data published by Bigler [9], An explanation 
for this phenomenon may be that the strongly increased levels of angiogenic factors 
(e.g. VEGF) [8] result in a ‘saturation’ of the vascular bed. It was argued that vessel
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density in tumours may exceed the metabolic requirements [38], Probably, this 
process may lead to a more uniform, strongly overvascularised tissue.
In this study no correlation was found between microvascular parameters and 
Gleason score. Conflicting results conceming this issue have been published in the 
literature. Arakawa et al [10] and Bettencourt et al [11] found a signifïcantly 
increased MVD with increasing Gleason score. Erbersdobler et al [39] found a 1.5 
fold difference between transition zone tumours, with a mean Gleason score of 5, and 
peripheral zone tumours with mean Gleason score of 7. Probably, the fact that only 
peripheral zone tumours were used exhibiting a small range of Gleason scores (score 
5 or higher) accounts for this.
Conclusion
In the present study application of an automated procedure to quantify vascular 
parameters showed significant differences between the vascular bed in tumour tissue 
as compared to normal prostate tissue. Mean and 75* percentile of MVD, MVA and 
MVP were increased in tumour, showing enhanced vascularity. In contrast, the 
heterogeneity in MVD, MVA and MVP was decreased in tumour as compared to 
normal tissue.
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Background The objective of this study was to analyze characteristics of lymphatic 
vasculature in normal and (peri)tumoral prostate tissue, applying accurate and 
objective quantifïcation techniques based on digital image analysis.
Methods Radical prostatectomy specimens of 27 patients were selected containing 
organ confmed peripheral zone tumors, which were restricted to one side of the 
prostate (pT2a). Lymph vessels were visualized by immunohistochemistry against 
D2-40. Lymphatic vessel density, perimeter and area were assessed over the entire 
tumor and corresponding contra-lateral normal tissue. Also, morphology (area, 
perimeter and diameter) of individual lymph vessels were measured in (peri)tumoral 
and normal tissue.
Results No differences were found in the overall lymph vasculature between tumor 
and normal peripheral zone. However, the area, perimeter and diameter of individual 
lymph vessel profiles were significantly decreased in (peri)tumoral as compared to 
normal tissue. No differences were seen for these parameters between peritumoral 
and tumoral area. Comparing the coëfficiënt of variation between compartments 
(normal, (peri)tumoral), no differences were observed for any parameter.
Conclusions Although differences exist between the morphology of individual lymph 
vessels in tumor versus normal tissue, the overall vascular bed (number and summed 
area and perimeter of lymphatics per area unit tissue) is unaffected in tumor. 
Peritumoral lymphatics resemble lymphatics in tumor tissue rather than normal 
lymphatics.
Key words Prostate cancer; Lymphangiogenesis; Digital image analysis
Introduction
The in vivo visualization of prostate cancer is continuously improving as a result of 
new developments in imaging techniques (MRI, ultrasound) and the use of contrast 
agents. The contrast enhancement in these imaging modalities reflects hemodynamic 
changes in the prostate, providing functional rather than anatomical data. Close 
comparison with detailed histopathology results has contributed to a better 
understanding of MRI data. Signals encountered in dynamic contrast enhanced -  MRI
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(DCE-MRI) depend on the influx and outflow of contrast agent which depends on 
vascular and non-vascular components. Examples are blood perfusion, microvessel 
density (MVD), vessel wall permeability, cell density, extracellular volume fraction, 
and extracellular matrix density [1], Lymphatics are part of the vascular structure and 
play an important role in tissue fluid homeostasis and in transport of lymph to the 
central circulation. Insight into the characteristics of the lymph vessel vascularity of 
normal prostate and prostate cancer will therefore increase the understanding of 
contrast-enhanced radiologie imaging.
As compared to the blood vasculature, relatively limited information is available 
conceming the tumor lymphatic vasculature of the prostate. This can be explained by 
the fact that for a long time no reliable lymphatic marker has been available [2, 3]. In 
the last ten years several specifïc antibodies to lymphatic endothelial cells have been 
identifïed (human vascular endothelial growth factor receptor-3 (VEGFR-3) [4], 
D2-40 [5], desmoplakin [6], and LYVE-1 [7]. It was shown that the topographic 
distribution of lymphatic vessels in the normal human prostate shows an increased 
density in the capsular area, around the ejaculatory ducts and in fibromuscular regions 
between the transition zone (TZ) and the peripheral zone (PZ) [8, 9]. In prostate 
cancer a significant decrease in lymphatic vessel density (LVD) was found in the 
intratumoral area in some studies but not in others [7, 10]. In studies by Zeng et al. 
and Roma et al. an increase in peritumoral LVD was found and peritumor lymphatic 
invasion correlated with lymph node metastasis [10, 11],
The objective of the present study was to analyze characteristics of the overall 
lymph vasculature (LVD, lymphatic vessel area (LVA), and lymphatic vessel 
perimeter (LVP)) in tumor and peritumor tissue as compared to normal prostate 
tissue. Next to these commonly studied parameters describing the gross overall 
vasculature, digital image analysis allowed us to study morphology (area, perimeter, 
diameter) of individual lymph vessel profïles in detail. The level of accuracy reached 




Twenty seven (n=27) radical prostatectomy specimens with unilateral peripheral zone 
pT2 tumors were included in this study. All patients showed negative resection 
margins and received no neo-adjuvant therapy. The age and serum PSA levels were 
obtained from patiënt history at time of radical prostatectomy. Prostatectomy
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specimens were handled according to a previously described protocol [12]. 
Specimens were cut into serial 4mm transverse shces perpendicular to the dorsal 
rectal surface. The slices were photographed using a CCD camera. An experienced 
uropathologist (CHvdK) marked the borders of the tumor on hematoxylin and eosin 
(H&E) stained sections. The Gleason grade and score were determined using the 2005 
ISUP Modified Gleason System [13]. Tumor volume was estimated as described [14].
For this study, a mirror image of equal size compared to the tumor was marked in 
the contra lateral normal peripheral zone tissue to be able to obtain a measurement 
uninfluenced by tumoral growth factors (e.g. VEGF-C, VEGF-D) and by possible 
preexisting regional or zonal differences in lymph vessel parameters in the normal 
prostate. The peritumoral compartment was defined as the area around the tumor 
compartment measured within the diameter of one lOx field (i.e. 1 mm from tumor 
edge ) containing benign glandular tissue. Mild to moderate chronic inflammation and 
various subtypes of atrophy were accepted as “normal” variations because of their 
high frequency of occurrence in prostates at the age at which adenocarcinoma occurs. 
Severe and extensive inflammation and multifocal high grade PIN however, were 
regarded as abnormal and excluded.
Immunohistochemistry
D2-40 immunohistochemistry was performed on sections serial to the H&E stained 
sections containing the marked regions of interest. A mouse anti-human D2-40 
monoclonal antibody (DakoCytomation, Copenhagen, Denmark, Clone D2-40) was 
used as the primary antibody.
Quantification of Lymphatic vascular structure
Automated mapping procedure
Automated analysis of prostate specimens was performed using a method described 
previously [14], using KS400 image analysis software(version 3.0, Carl Zeiss, 
Germany). Briefly, a D2-40 stained transverse section through the entire prostate was 
scanned exhaustively and pseudocolor mappings were produced expressing vascular 
parameters assessed in local neighborhoods. Quantitative data for lymph vessel 
density (LVD, defined as the number of lymph vessels per unit measurement area), 
integrated perimeter of lymph vessels (LVP), and integrated area of lymph vessels 
(LVA) were extracted from scanned specimens in manually dclineated regions 
comprising the tumor and contra lateral normal tissue.
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Interactive measurement
To be able to study morphology of individual lymph vessels in more detail, in each 
specimen flve manually selected microscopie regions were analyzed in the tumor, 
peritumoral and normal area using a previously described procedure [15]. Because of 
the limited number of lymphatic vessels present in the prostate, fïelds containing 
multiple lymph vessels were selectively sampled if available. Images (measuring 0.73 
mm2) were acquired using an RGB-CCD camera (DXC-950P, Sony) connected to an 
Axiophot microscope (Carl Zeiss, Germany) using a lOx objective (Plan Neofluar, 
NA=0.3), resulting in a specimen level pixel size of 1.28 x 1.28(j.m2. All image 
acquisition and processing were performed using KS400 image analysis software 
(version 3.0, Carl Zeiss, Germany). Positively stained vascular profiles were 
automatically recognized, results were shown on the computer monitor and 
interactive correction was performed if required. Subsequently, the software 
calculated the perimeter, area and diameter of all individual vascular profiles in a 
field of vision.
Statistical Analysis
The skewed distribution observed for most parameters could be transformed to an 
approximately normal distribution using log -  conversion (data not shown). 
Comparison of data from different regions (peritumoral, tumoral and normal tissue) 
was performed using either paired t-tests (2 regions) and repeated measures analysis 
of variance (Anova) with Sidak correction of p-values in multiple comparison testing. 
The relationship of vessel parameters with tumor volume, PSA and Gleason score 
was analyzed using Pearson correlation coefficients. All statistics were performed 
using SPSS software (SPSS Inc, Chicago, II). All probabilities from statistical tests 
are based on two-sided testing, significance being defined as p<0.05.
Results
Mean patiënt age was 60.4 years (range 47 -  70 years) with mean preoperative PSA 
of 6.43 ng/ml (range: 2.33 -  12.1 ng/ml). Tumors were generally small with a volume 
ranging from 0.3 -  4.8 cm3 (mean 1.56 cm3). The Gleason grade ranged from 2 - 5  
(mean 3.33) with mean Gleason score 6.5 (range 5 - 9 )  (Table I).
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Table I: Clinicopathological data o f 27 adenocarcinomas o f the prostate.
Patiënt parameters Number of patients (%)
Age (years)
< 6 0 10 (37)






< 7 15 (56)
> 7 12 (44)
PSA (ng/ml)
<10 25 (93)
> 10 2 (  7)
D2-40 immimohistochemistry resulted in a clearly visible brown sediment on 
lymphatics (Figure 1). The automated pseudocolor mappings provided an overview of 
the spatial distribution of the lymphatic vasculature, clearly showing the limited 
amount of lymphatics (see example in Figure 2).
Figure 1: Examples of immunohistologically stained (MAb D2-40) prostate tissue, 
showing strongly positive lymphatic vessels. Small or collapsed lymphatics were 
frequently found in both the tumor (T) and peritumoral (P) tissue. In normal (N) 
tissue the lymph vessels appeared dilated.
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Figure 2: Automated mapping images, illustrating Lymph Vessel Density (LVD) and 
Lymph Vessel Perimeter (LVP). LVD an LVP are shown as pseudocolors, with the 
corresponding scale shown on top. White lines demarcate the borders o f the mapping 
and o f the tumor (T— Tumour) measured.
No clear spatial organization could be detected in the lymphatics layout; rather they 
were randomly distributed throughout the prostate. This is reflected in the fact that no 
significant differences existed between normal tissue and tumor tissue for any of the 
vessel parameters (LVD, LVA, LVP) assessed using automated mapping (Table II). 
Heterogeneity of lymph vasculature between tumor and normal lymph vessels, as
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expressed in the coëfficiënt of variation (CV, defined as the ratio between Standard 
deviation and mean value) also did not show any differences (Table II).
Table II: Summary statistics and statistical test results for mapping data
Normal tissue Tumor tissue T-test
Parameter Statistic Mean Std.dev Mean Std.dev Mormal vs tumor
LVD
(1/mm2)
Mean 106 2 48 107 216 Ns
P75 16.9 3.16 16.5 3.0 Ns
c v 734 109 71 9 9 1 Ns
LVA
Mean 1.1 0.7 1.0 0.5 Ns
(%) P75 14 09 12 0 65 Ns
c v 147.5 33.2 153.9 34.2 Ns
LVP
(mm/mm2)
Mean 1.5 04 1 39 03 Ns
P75 2.17 0.5 2 0.4 Ns
c v 91 .2 12 1 91 1 105 Ns
Paired T-tests performed on log transformed data; P75 = 75th percentile; CV= 
coëfficiënt of variation. Lymph vessel density (LVD), Lymph vessel area (LVA), 
Lymph vessel perimeter (LVP) do not show any significant differences between 
normal and tumor tissues.
Figure 3 shows the (log converted) ratio between parameters assessed in different 
compartments. A value of 0 indicates a parameter was identical in two compartments, 
whereas values exceeding 0 indicate an increase in the fïrst compartment and vice 
versa. Figure 3 shows a comparison of lymphatic parameters measured in tumor 
versus contra lateral normal tissue using interactive and automated mapping 
measurements with each circle representing a single case (N=27). Both the mean 
value and CV for lymphatic parameters assessed by the automated method cluster 
around 0, indicating identical parameter values in these two compartments.
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Figure 3: Comparison o f parameters o f lymphatics measured in tumor versus 
contralateral normal tissue. Each circle represents a single case. A value o f zero 
means no difference exists between tumor and normal tissue; positive values indicate 
an increased value in tumor and negative values indicate increased value for normal 
tissue. Measurements wereperformed with the automated mappingprocedure (n=27; 
LVD = lymphvessel density, LVA=lymphvessel area, LVP=lymphvessel perimeter) 
and interactively (n=27)
Comparison of parameters of lymphatics measured 
in tumor versus contra lateral normal tissue
Results of the interactive measurement method are shown in Table UI. Highly 
statistical significant differences were observed for mean lymph vessel area, 
perimeter and diameter in normal vs. peritumoral, and normal vs. tumor tissue (Table 
IV). In contrast, vessel characteristics only showed minor differences comparing 
peritumoral vs. tumor lymphatics. The CV only proved significant for diameter in 
normal vs. tumor tissue (p<.01). Figures 3 and 4 graphically show these data.
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TABLEIII: Summary statistics for Interactive measurement data
Normal tissue Peritumoral tis. Tumor tissue
Parameter Statistic Mean Std dev Mean Std.dev Mean Std dev
Area (|im2) Mean 2647 2039 1207 786 6 980 7 9708
CV 1.7 0.6 1.6 0.6 1.4 0.4
Perimeter (jim) Mean 272 947 183 9 66 144.4 4748
CV 1.1 0.2 0.9 0.3 0.9 0.2
Diameter (nm) Mean 20 91 9.25 16 05 5 7 1498 7.95
cv 0.9 0.3 0.8 0.2 0.7 0.2
A comparison of lymph vessel morphology (area, perimeter, diameter) with normal, 
peritumoral and tumor tissue.
TABLE IV: Statistical test results for interactive measurement data
Parameter Statistic N vs P P vs T N vs T
Area Mean p<001 ns p<001
cv ns ns ns
Perimeter Mean p<001 p< 01 p<.001
cv ns ns ns
Diameter Mean P<.01 ns p<001
cv ns ns p<.01
Tests performed using repeated measures ANOVA on log transformed data. Sidak 
correction for p-values was used in multiple comparisons. The morphological 
parameters area, perimeter and diameter show significant decrease in (peri)tumoral 
tissue compared to normal tissue. Lymph vessel characteristics in tumor tissue were 
not different from those in peritumoral tissue. Variability in lymph vessel parameters 
(expressed in the CV) were mostly constant over all tissue compartments.
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Figure 4: Comparison of mean values o f lymphatic parameters measured in tumor, 
peritumoral and contra lateral normal tissue. Each circle represents a single case. 
See legend to Figure 4 for explanation o f the y-scale used
Comparison of mean values of lymphatics parameters measured 
in tumor, peritumoral and contra lateral normal tissue
No relation was found between measured lymph vessel characteristics and age, tumor 
volume, Gleason score and PSA (data not shown).
Discussion
The complex dynamics of (blood, lymph) fluid transport through human tissues, and 
alterations therein caused by malignant processes form the basis of success of DCE- 
MRI. Understanding these dynamics will consequently aid the interpretation of DCE- 
MRI signals, and may elucidate why certain tumors are more easily detected than 
others. In a previous study we focused on the microvascular bed in peripheral zone
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prostate tumors [14]. In the present study the lymphatic bed was analyzed in such 
tumors, because lymphatics are also an important factor related to tissue fluid 
dynamics. The lymphatic bed may in this context be regarded as complementary to 
the microvasulature. Contradictory to most other studies, in the present study no 
differences were found between tumor and normal tissue regarding the extent of the 
lymphatic bed as expressed in the lymph vessel density (LVD). In addition to the 
gross overall lymphatic density, we also assessed the geometry of individual lymph 
vessel profïles. Significantly smaller (area, perimeter and diameter) profiles were 
observed intratumorally and in the tumor periphery as compared to normal prostate. 
The degree of variation in these parameters was identical in all compartments.
Although previous studies agree on the intratumoral LVD being significantly 
smaller than the peritumoral LVD, inconsistent results were found conceming normal 
prostate tissue. Normal prostate was found to possess increased [7, 11, 16], 
similar [10] or even decreased [17] LVD compared to tumor tissue. Differences 
between such findings may often be attributed to variations in methodology [15]. In 
these studies, microscopie areas for assessment of LVD were selected using a variety 
of techniques: exhaustive sampling [11], random sampling [10] and identification of 
one [16] or several [7, 17] subjective hot spots. Also, the group of patients 
investigated ranged from containing 64% low grade (Gleason grade < 7) [17] to only 
9% low grade tumours [7]. Expectedly, these variations will influence study outcome.
In the present study, an objective procedure for assessment of LVD and related 
parameters LVP and LVA was used [14]. Because transverse sections through the 
entire prostate were measured, parameters were assessed in the entire tumor as well as 
in the most representative (contra lateral) normal tissue. This method differs from 
previously published studies, in which only a ‘representative’ part of tumors was 
measured. Selection of the tumor part to be analyzed introducés undesirable bias to 
these studies. Also, by measuring normal tissue distant from the tumor, the influence 
of tumor secreted factors (e.g. VEGF) on the LVD was kept to a minimum in the 
present study. All other studies define normal tissue as tissue at a distance exceeding 
1 mm (in one case 2 mm [16]) from the tumor edge. It is questionable whether tissue 
this close to the tumor may be regarded as entirely normal. Moreover, the degree in 
which such normal tissue is influenced by the tumor may depend on tumor 
characteristics (e.g. Gleason score).
No previous studies quantitatively assessed geometry of individual lymph 
vessels. However, it was described that lymph vessels are either small and collapsed 
or large with open lumina in normal prostate [10,17]. In contrast, presence of only 
small collapsed vessels in tumor tissue was observed [10,17], These observations 
match our observation of tumor lymphatics being smaller compared to normal tissue.
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Interestingly, Kim found mainly large lymphatics in the peritumoral region whereas 
Zeng describes small, collapsed vessels in this region. In the present study 
peritumoral lymph vessels seem to resemble tumor lymphatics rather than normal 
lymphatics, matching Zengs’ observation.
From these results, we hypothesize that overall there is no difference in LVD 
between tumor and normal tissue. Results from previous studies may be influenced by 
selection criteria for normal and tumor tissue, and by criteria for selecting 
measurement regions within these compartments. A growing tumor mass is obliged to 
induce lymph angiogenesis to remain at the same overall LVD, as observed in the 
present study. Our results seem to indicate a limited amount of lymphangiogenesis. 
This is supported by the fact that prostate tumors show upregulation of VEGF-C [18], 
The fact that in the present study intratumoral and peritumoral lymphatics were 
significantly smaller compared to normal lymphatics supports this view. Because no 
large scale lymph angiogenesis takes place, differences in the morphology of 
individual lymphatics were not suffïciently reflected in the parameters LVA and LVP 
to reach signifïcance in the present study. We therefore disagree with Trojan who 
argued that destruction of lymphatics takes place within prostate tumors [7].
The results of this study indicate that contrast enhancement and late washout of 
Gadolinium in DCE-MRI are not caused by alterations in the number of tumor 
lymphatics. In contrast, in a previous study we showed that increased numbers of 
blood vessels may be an important factor [14]. Diminished drainage due to smaller 
and less functional lymphatic capillaries may still have a significant impact on DCE- 
MRI signals.
Conclusions
By applying accurate and objective computerized measurement techniques, we were 
able to study both characteristics of the overall lymphatics and of individual 
lymphatic profïles, in tumor, peritumor and representative normal prostate. Our 
results are suggestive for a limited degree of lymphangiogenesis in low grade 
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Background The objective of this study was comparison of characteristics of the 
microvasculature in transition zone tumor (TZT) and benign nodular hyperplasia 
(BPH) with normal prostatic transition zone (NTZ), applying accurate and objective 
quantification based on digital image analysis. Results of this study may increase 
understanding of prostate dynamic contrast enhanced (DCE) MRI analysis.
Methods Radical prostatectomy specimens of 28 patients containing TZT ranging 
from pT2 -  pT4 were used. In 11 patients a concomitant peripheral zone tumor (PZT) 
was present. Microvessels were visualized by CD31 immunohistochemistry. 
Specimens were scanned using a computer controlled microscope with automatic 
recognition of microvessels. Pseudocolor maps were produced displaying microvessel 
density, perimeter, and area of an entire prostate transection. Mean, 75th percentile 
(p75) and coëfficiënt of variation (CV) were calculated automatically in manually 
indicated areas of the tumor and corresponding contralateral normal tissue, and BPH.
Results Large variability was seen in TZT microvascular parameters, indicating 
presence of patients having both hypo and hypervascularised tumors compared to 
NTZ. In contrast, areas of BPH showed a more consistent increase in vascular 
parameters, with decreased CV. Analysis of PZT confirmed results of our previous 
study, with mean and p75 of all vascular parameters being significantly increased and 
a decrease in CV. No correlation was found for clinicopathological parameters and 
microvascular parameters.
Conclusion Microvasculature of transition zone tumor showed increased 
heterogeneity compared to BPH and peripheral zone tumors, possibly explaining the 
difficulty of TZT detection on DCE-MRI.
Introduction
Prostate cancer is a heterogeneous disease with variable clinical outcome. The site of 
origin in the prostate is a potential prognostic factor. In approximately 20% to 25% of 
prostate cancers the tumor arises in the anterior half of the prostate: in the transition 
zone (TZ), in the anterolateral hom of the peripheral zone (PZ) or in the anterior 
fibromuscular stroma area [1-3], collectively called anterior predominant or more 
conventionally TZ tumors, although strictly speaking anterolateral hom PZ tumors
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should not be included in this group. Diagnosing these tumors is challenging. Due to 
their anterior location most TZ cancers are not palpable at rectal examination, not 
visible by transrectal ultrasound (TRUS) and less often detected by Standard prostate 
biopsy schemes, because they are often beyond the posterior transrectal biopsy 
placement [4], except at the apex of the gland where the anterior portion of the 
prostate is much closer to the rectal surface. An increasing PSA with repeated 
negative biopsy series is often the only indicator of its presence [5],
TZ tumors are generally considered to be less aggressive and therefore clinically 
less significant than PZ tumors, but it is a moot question whether clinicopathological 
differences can be explained by the anatomical location alone or also by intrinsic 
biological differences. The TZ boundaiy consisting of a fibrous band separating TZ 
and PZ probably acts as a relative barrier to tumor extension allowing for a larger 
nodular outgrowth before extraprostatic extension occurs [1]. Due to this anterior and 
therefore less palpable location, TZ tumors tend to be of lower clinical stage, but 
show larger tumor volume and higher preoperative PSA. At radical prostatectomy 
(RP), they have a lower frequency of extraprostatic extension [6-9], possibly also as a 
result of fewer penetrating nerves in the anterolateral region [10], and of seminal 
vesicle invasion. They tend to have a more favorable biological behavior [11-14], 
especially when matched for preoperative PSA and tumor volume [7, 12], but not 
Gleason grade pattem [7], pathological stage or surgical margin status [7, 15], High 
Gleason grade pattem appears to cancel the effect of tumor location [7]. Other recent 
studies could not confirm anterior location itself as an independent prognostic 
factor [16, 17].
As mentioned, preoperative detection is challenging (also when using MRI) 
because of the poor and inhomogeneous signal in the anterior compartment. TZ 
tumors are difficult to distinguish from benign prostatic hyperplasia (BPH). TZ tumor 
detection can be improved by combining T2-weighted imaging with Tl-weighted 
dynamic contrast enhanced MRI (DCE-MRI) [18, 19], MR spectroscopy [20], or 
diffusion-weighted imaging [21, 22], An improved MRI detection can allow for MRI- 
guided biopsies [23], Using DCE-MRI, prostate cancer is usually visualized based on 
shorter time to peak and increased peak enhancement as well as late wash-out, 
properties which can partly be attributed to increased vascularization of the tumor. 
However, distinction of TZ tumor from benign prostatic hyperplasia is often difficult, 
because the latter also shows an enhanced signal. Prostate cancer, especially PZ 
tumors, has overall an almost two-fold increase in microvascularity [24], Only one 
study compared microvascularity in TZ tumors and PZ tumors, and found a 
signifïcantly lower mean microvessel density (MVD) in TZ tumors than in PZ tumors
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(68.5 versus 104 per mm2), but they did not compare the results with normal prostate 
tissue [11].
The aim of this study is comparison of microvascularity parameters between TZ 
tumors, normal TZ and PZ prostatic tissue and benign nodular prostatic hyperplasia 
(BPH), gaining insight in potential differences in microvascularity that could 
contribute to the understanding of e.g. the results of DCE-MRI. An optimized 
quantifïcation method was used, with computer controlled microscope and scanning 
stage and automatic vessel recognition, producing a pseudo color mapping of an 
entire prostate transection. Digital image analysis was used to construct spatial 
mappings for MVD, vascular area and vascular perimeter. In this way vascular 
parameters could be assessed objectively avoiding subjective hot spot selection [24].
Materials and methods 
Study Population
Twenty-eight patients treated in our centre who underwent a preoperative MRI 
followed by radical prostatectomy (RP) between 2006 and 2009 in which a TZ tumor 
was identified on RP specimens were included. The anterior predominant location of 
the tumor was assessed according to the criteria defined by McNeal et al [8, 24], 
Briefly, a tumor focus was assigned to the TZ when at least 70% of its area was 
estimated to be present in the TZ zone; pT2-pT4 tumors were included in this study 
(Table I). None of the patients received neo-adjuvant therapy. Patiënt age and serum 
PSA levels at time of RP were obtained from patiënt history. Within this group of 28 
patients, 11 concomitant PZ tumors and 23 glandular BPH areas were also identified.
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TABLE I: Clinicopathological data o f transition zone tumors and concomitant 
peripheral zone tumors
Transition zone tumors 
(n = 28)
Peripheral zone tumors 
(n = 11)
Age in years
median (range) 65 (55 -  72) 6 4 (5 6 -7 1 )
PSA (ng/ml)
mean (range) 11.23 (0 .1 -4 7 ) 8.51 (0 .9 -2 4 )
Tumor volume (cm3)
median (range) 1.2 cm3 (0.11 -11 .3 ) 0.54 cm3 (0 .10 -2 .7 )
< 1 cm3 12 (43%) 8 (73%)
1 - 4  cm3 10(36%) 3 (27%)
> 4 cm3 6(21%) -
Tumor stage
pT2a 1 ( 4%) 0 ( 0%)
pT2c 17 (61%) 6 (55%)
pT3a 6 (21%) 4 (36%)
pT3b 2 (7% ) 1 ( 9%)
pT4 2 (7% ) -
Gleason score
mean (range) 5.9 ( 4 -8 ) 5.6 ( 4 - 7 )
<6 12 (43%) 5 (45%)
6 7 (25%) 5 (45%)
7 8 (29%) 1 (9%)
>7 1 (4%) -
Surgical margins
Positive 17(61%) 7 (64%)
Negative 11 (39%) 4 (36%)
Prostatectomy specimens were handled according to a previously described 
protocol [24]. Briefly, specimens were cut into serial 4mm transverse slices 
perpendicular to the dorsal rectal surface. The slices were photographed using a CCD 
camera. Apical and basal slices were then sectioned para sagittally Depending on the 
size of the prostate, the remaining slices were divided into halves or quadrants in 
order to fit routine cassettes for diagnostic purposes. An experienced uropathologist 
(CAHK) marked the borders of the tumor and BPH area on hematoxylin and eosin 
(H&E) stained sections. The Gleason grade and score were determined for each tumor
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according to the modifïed Gleason grading system [25]. Tumor volume was estimated 
by measuring the largest tumor diameter and the diameter perpendicular to the largest 
diameter in all tissue sections containing tumor. Section tumor area was calculated 
from these diameters by assuming elliptical tumor shape, integrated over all sections 
and multiplied by the section thickness to arrive at the estimated tumor volume. For 
this study, a mirror image of equal size compared to the tumor was marked in the 
contra lateral normal TZ tissue (without cancer and without significant BPH or 
inflammation). In addition, an area of comparable size was delineated in the normal 
PZ, as well as (when present) PZ tumor and BPH. Mild to moderate chronic 
inflammation and various subtypes of atrophy were accepted as “normal” variations 
because of their high frequency of occurrence in prostates at the age at which 
adenocarcinoma occurs. Severe and extensive inflammation and high grade PIN 
however, were regarded as abnormal and excluded.
Immunohistochemistry
CD31 immunohistochemistry was performed on sections serial to the H&E stained 
sections containing the marked regions of interest. Tissue sections of 4 prn were 
deparaffinized, rehydrated and pretreated using an EDTA antigen retrieval system. 
Endogenous peroxidase activity was blocked by using 3% H2C>2 in methanol for 10 
minutes after which sections were rinsed with water and phosphate buffered saline 
(PBS). A mouse anti-human CD31 monoclonal antibody (DakoCytomation, 
Copenhagen, Denmark, Clone JC70A) was used as the primary antibody at a dilution 
of 1:10. The specimens were incubated ovemight at 4DC. Specimens were then 
washed in PBS and incubated with PowerVision (Immunologie PowerVision Poly- 
Hrp-Anti Ms/Rb/Rt IgG Biotin-free, Immunologie, The Netherlands) for 30 minutes. 
Specimens were washed in PBS for 10 minutes and further incubated with Power- 
DAB (Immunologie, The Netherlands) for 5 minutes creating clearly visible brown 
sediment on detected areas. The specimen was then washed in water, dehydrated and 
mounted with Quick-D (Klinipath, The Netherlands). No counter staining was used.
Quantification of microvasculature
Automated analysis of prostate specimens was performed using a method described 
previously [24], using KS400 image analysis software (version 3.0, Carl Zeiss, 
Germany). Briefly, a CD31 stained transverse section through the entire prostate was 
scanned exhaustively and pseudo color mappings were produced expressing vascular 
parameters assessed in local neighborhoods (Figure 1A-C). Quantitative data for 
MVD, integrated perimeter of microvessels (MVP), and integrated area of 
microvessels (MVA) were extracted from scanned specimens in manually delineated
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regions comprising the tumor, contra lateral normal tissue and BPH (Figure 1A-C). 
Over each region, next to the mean parameter values also the coëfficiënt of variation 
(CV; being defïned as 100% x Standard deviation / mean) and the 75th percentile were 
calculated. The CV is a measure of variability, whereas the percentile focuses on areas 
with larger parameter values, somewhat comparable to the frequently used hot-spot 
value [24].
Figure 1: This figure illustrates pseudocolor heat maps constructed by data from 
automated microscopy for A: Microvessel density, B: Microvessel area, C: 
Microvessel perimeter in Transition zone tumor (TZT), Normal transition zone (NTZ), 
Benign prostatic hypertrophy (BPH), Peripheral zone tumors (PZT), and Normal 
peripheral zone (NPZ) o f the prostate. The corresponding actual CD 31 stained 
histological images (lOx magnified) are shown in D, E ,F ,G ,H
NTZ 110 “ NT7
o ,  °  - . ■ e x  < 3
. '' NP7 ’ n„  ■. ■ ^ 1 —
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Statistical analysis
Comparisons between different regions were performed using paired t-tests on log- 
transformed data. Correlations were calculated by Pearson correlation analysis on log- 
transformed data. All probabilities from statistical tests were based on two-sided 
testing, significance being defined as p<0.05. Statistics were performed using SPSS 
software (SPSS Inc, Chicago, II, USA).
Results
Assessment of MVD, MVA and MVP was performed on 28 TZ tumors, 11 
concomitant PZ tumors and 23 areas of BPH, as well as areas of normal TZ and PZ. 
Pathological characteristics are given in Table I. Mean patiënt age was 64.6 years 
(range 55-72 years), with mean preoperative PSA 11.2 ng/ml (range 0.10-47.0 ng/ml). 
TZ tumors showed a median tumor volume of 1.2 cm3 (range 0.11-11.3 cm3) with 
Gleason grades 2 to 4 (mean 2.9; mean Gleason score 5.9). The concomitant PZ 
tumors (N=ll) were usually smaller with a tumor volume ranging from 0.10 - 2.7cm3 
(median 0.54 cm3). PZ tumors ranged from Gleason grade 2 to 4 (mean 2.7) with a 
mean Gleason score of 5.6 (Table I).
Vascular characteristics of TZ tumors, areas of glandular BPH and normal PZ 
were compared to normal TZ vasculature using paired t-tests. Results are shown in 
Tables II -  IV and in Figures 2 - 4 .  Comparing TZ tumor to normal TZ, a tendency 
towards an increase in the extend of the vascularity up to a factor 1.4 was observed in 
TZ tumors (expressed in mean and p75 of MVD, MVA and MVP) with a 
corresponding decrease in the variability (expressed in the CV), but none of these 
comparisons reached significance, except for the CV of the MVA (p<0.05; Table III 
and Figure 2). This means that in the TZ tumors the diameter of the vessels showed 
less variation than in the normal TZ. Similar, be it less pronounced, effects were seen 
when comparing normal PZ with normal TZ tissue, with only the CV of MVD and 
MVP being significantly decreased in the normal PZ, indicating more variation of 
vascularity in the normal TZ.
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TABLE II: Microvessel density (MVD) for transition zone (TZ) tumours, averaged 
over 28 patients. Coëfficiënt o f variation defined as 100% x Standard deviation/mean. 
Ratio is the data from TZ tumour, BPH, and normal PZ compared to normal TZ tissue
Normal TZ TZ Tumor BPH Normal PZ
Mean Mean Ratio Mean Ratio Mean Ratio
(reference)
Mean (1/mm2)
Mean 55.4 63.7 1.2 58.7 1.1 65.0 1.22
SD 19.6 22.4 0.55 22.0 0.25 25.2 0.45
Range 23.7-123 29.3-114 0.62-2.9 29.1-101 0.60-1.5 22.7-130 0.53-2.1
Coëfficiënt of variation (%)
Mean 67.1 62.0 0.94 65.0 0.92 60.3** 0.92
SD 10.8 10.7 0.21 11.4 0.13 12.0 0.19
Range 52.0-91.2 42.2-92.6 0.68-1.5 44.5-89.4 0.77-1.2 41.6-87.6 0.65-1.4
75tb percentile (1/mm2)
Mean 77.6 88.4 1.2 82.0 1.1 90.5 1.2
SD 25.9 30.1 0.54 28.5 0.24 32.1 0.42
Range 32.3-159 42.3-159 0.63-2.9 42.3-141 0.63-1.5 32.3-169 0.54-2.3
** Significantly different from normal TZ tissue at the 0.01 level.
Table III: Microvessel area (MVA) for transition zone (TZ) tumours, averaged over 28 
patients. Coëfficiënt o f variation defined as 100% x Standard deviation/mean. Ratio is 
the data from TZ tumour, BPH, and normal PZ compared to normal TZ tissue
Normal TZ TZ Tumor BPH Normal PZ




1.0 1.2 1.3 1.1* 1.2 1.1 1.1
SD 0.65 0.74 0.72 0.70 0.39 0.88 0.41
Range 0.25-3.3 0.35-2.8 0.39-3.1 0.29-2.8 0.52-2.2 0.24-4.3 0.49-2.0
Coëfficiënt of variation (%) 
Mean 118 103* 0.91 107* 0.92 110 0.97
SD 23.5 18.2 0.23 23.0 0.81 27.1 0.33
Range 87.5-173 74.4-150 0.46-1.3 75.5-160 0.59-1.3 60.5-179 0.63-2.0
75"' percentile (%) 
Mean 1.3 1.6 1.4 1.5* 1.3 1.4 1.1
SD 0.80 1.0 0.75 0.94 0.41 1.1 0.42
Range 0.31-4.1 0.47-3.9 0.40-3.3 0.39-3.8 0.56-2.3 0.31-6.0 0.44-2.0
* Significantly different from normal TZ tissue at the 0.05 level.
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Table IV: Microvessel area (MVP) for transition zone (TZ) tumours, averaged over 
28 patients. Coëfficiënt o f variation defined as 100% x Standard deviation/mean. 
Ratio is the data from TZ tumour, BPH, and normal PZ compared to normal TZ 
tissue
Normal TZ TZ Tumor BPH Normal PZ
Mean Mean Ratio Mean Ratio Mean Ratio
(reference)
Mean (mm/mm2)
Mean 3.31 4.0 1.3 3.8* 1.2 3.7 1.2
SD 1.6 1.8 0.69 1.9 0.31 2.02 0.45
Range 0.97-9.1 1.4-8.1 0.49-3.1 1.2-8.2 0.58-1.8 0.89-10.3 0.43-2.3
Coëfficiënt of variation (%)
Mean 79.1 74.9 0.97 75.4* 0.94 71.8* 0.92
SD 13.7 16.0 0.24 17.6 0.16 17.5 0.21
Range 55.5-109 47.5-114 0.64-1.5 48.5-108 0.73-1.4 44.8-113 0.61-1.5
75*11 percentile (mm/mm2)
Mean 4.7 5.6 1.3 5.3* 1.2 5.1 1.1
SD 2.2 2.5 0.65 2.5 0.29 2.6 0.42
Range 1.5-11.7 1.9-11.3 0.47-3.0 1.8-11.0 0.63-1.7 1.3-13.6 0.42-2.2
* Significantly different from normal TZ tissue at the 0.05 level.
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Figure 2: Logarithm of ratio between parameters (mean, coëfficiënt o f variation and 
75th percentile) calculated over the tumour area and corresponding contra lateral 
normal prostate tissue. A value o f 0 indicates no differences, with log ratio >0 
indicating an increased value in tumour. Shown are microvessel density (MVD), 
microvessel area (MVA) and microvessel perimeter (MVP). Patients are represented 
by a circle
Figure 3: Logarithm o f ratio between parameters (mean, coëfficiënt o f variation and 
75th percentile) calculated over the BPH area and corresponding contra lateral 
normal transition zone prostate tissue. A value o f 0 indicates no differences, with log 
ratio >0 indicating an increased value in BPH. Shown are microvessel density 
(MVD), microvessel area (MVA) and microvessel perimeter (MVP). Patients are 
represented by a circle
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Figure 4: Logarithm o f ratio between parameters (mean, coëfficiënt o f variation and 
75th percentile) calculated over the normal peripheral zone and corresponding contra 
lateral normal transition zone prostate tissue. A value o f 0 indicates no differences, 
with log ratio >0 indicating an increased value in peripheral normal zone. Shown are 
microvessel density (MVD), microvessel area (MVA) and microvessel perimeter 
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Comparison of glandular BPH versus normal TZ vascular parameters showed an 
increase in mean and 75* percentile of MVD, MVA and MVP (reaching statistical 
significance only for MVA and MVP) with a decrease in the CV of these parameters. 
This indicates that the vessels in glandular BPH are generally uniformly larger than in 
normal TZ. Comparing PZ tumor with normal PZ, significant differences were 
observed for all parameters, which is in agreement with our previous study on 
vascularity in organ-confïned PZ tumors (Figure 5) [24],
Figure 5: Logarithm o f ratio between parameters (mean, coëfficiënt o f variation and 
75th percentile) calculated over the tumour area and corresponding contra lateral 
normal prostate tissue. A value o f 0 indicates no differences, with log ratio >0 
indicating an increased value in tumour. Shown are microvessel density (MVD), 
microvessel area (MVA) and microvessel perimeter (MVP). Patients are represented 
by a circle
Correlation analysis was performed to study a possible relationship between TZ 
tumor and normal TZ and likewise for PZ tumor and normal PZ tissue (Table V). A 
positive linear relationship was observed for the magnitude (mean and p75 but nor for 
CV) of MVA and MVP for TZ tumor versus normal tissue. For PZ tumor versus 
normal tissue, all statistics (mean, CV and p75) were signifïcantly correlated for all 
microvascularity parameters (MVD, MVA and MVP). No correlation was found 
between clinicopathological parameters (age, PSA, tumor volume, Gleason grade and 
Gleason score) and vascular parameters (MVD, MVA and MVP) in any prostatic 
region.
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Table V: Correlation analysis o f microvascular parameters in TZ tumor versus 
normal TZ and PZ tumor versus normal PZ
TZ tumor vs normal PZ tumor vs normal
Corr.coef. p-value Corr.coef. p-value
MVD
Mean 0.34 ns 0.73 <0.05
CV 0.11 ns 0.68 <0.05
p75 0.33 ns 0.66 <0.05
MVA
Mean 0.62 <0.001 0.87 <0.001
CV -0.22 ns 0.82 <0.01
p75 0.62 <0.001 0.84 <0.01
MVP
Mean 0.49 <0.01 0.78 <0.01
CV 0.21 ns 0.85 <0.01
p75 0.51 <0.01 0.74 <0.05
ns -  not significant
Discussion
In this study, a quantitative assessment of the vascular bed of 28 TZ tumors was 
performed; using computerized whole slide automated digital analysis. Data in the 
present study indicate a tendency (not reaching statistical significance) towards an 
overall increase in the extent of the vascular bed in TZ tumor as compared to normal 
TZ, with a lower variability of the vascular parameters. Variability over patients, 
however, is large, with patients showing both increased and decreased vascularity in 
the tumor. In contrast, the vascular bed in glandular BPH compared to normal TZ 
shows an overall smaller but more consistent increase in vascular parameters, with 
decrease in the variability of these parameters. For individual patients, this results in 
glandular BPH (if present) being mostly hyper-vascularized compared to normal TZ, 
with the TZ tumor possessing either increased or decreased numbers of bloodvessels 
compared to both normal TZ and glandular BPH regions.
To the best of our knowledge, this is the first study, which compares 
microvascularity in TZ tumors with normal TZ prostatic tissue. The lack of a 
consistent increase in microvascularity in TZ tumors is in contrast with the increase in 
microvascular parameters (MVD, MVP and MVA), which was observed in PZ 
tumors, both in the present study and in our previous study on organ confïned PZ
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tumors [24], We previously found up to an 1.8-fold increase for these parameters in 
PZ tumors, where other studies have reported a 1.5- to 2.4-fold increase in MVD for 
prostate cancer [26-29]. However, in contrast to the present study, in these studies no 
distinction in zonal origin of the tumors was made. Our fïndings are in agreement 
with those of Erbersdobler et al [11], who did compare the MVD of volume matched 
TZ tumors and PZ tumors, and found a significantly lower mean MVD in TZ tumors 
than in PZ tumors (68.5 versus 104 per mm2; p=0.0002, indicating a 1.5-fold 
difference). In this latter study no attempt was made to compare TZ tumors with 
normal TZ.
The differences observed in our studies between the vascular characteristics of 
TZ and PZ tumors may well reflect differences observed with respect to the 
detectability of prostate tumor on DCE-MRI. Whereas PZ tumors are mostly 
detectable because of a strong increase in signal (probably reflecting increased 
perfusion of the tumor), detection rates of TZ tumors are lower. TZ tumors may either 
show an increase or decrease of the DCE-MRI signal compared to its background, 
which consists of BPH, normal TZ tissue or both. BPH nodules in the TZ are strongly 
enhanced in DCE-MRI to the same or even a higher degree than TZ tumors [18]. This 
is in agreement with the results of the present study, in which PZ tumors always 
showed an increase in vascular parameters, whereas TZ tumors showed large 
heterogeneity. Presence of BPH in this compartment of the prostate hampers 
detection even further.
On patiënt level a strong positive correlation was observed between PZ tumor 
and normal PZ for all vascular parameters. A similar, be it weaker, correlation was 
seen for TZ tumor versus normal TZ. These data may indicate a stronger and more 
consistent role for pro-angiogenic factors in PZ tumors compared to TZ tumors. 
However, only few biological studies have been performed related to the zonal origin 
of prostate cancer and thus far no differences in VEGF levels have been reported [13]. 
The lack of a consistent increase in the microvascularity in TZ tumors as compared to 
PZ tumors, which could not be explained by differences in the basic microvasculature 
of the two zones, favors the theory that intrinsic biological differences exists between 
the two zonal tumor types. These are, at least partly, responsible for different clinical 
behavior. There are several arguments to support this theory.
Seen from a histomorphological point of view, most studies reported a lower 
mean Gleason Score in TZ tumors [30-33], especially when matched for tumor 
volume [11], although this was not found by all investigators. In the present study, no 
correlation was found between microvascular parameters and tumor volume. The 
median tumor volume was even larger in the TZ tumors than in the PZ tumors, which 
makes the difference in microvascular parameters between the tumors even more
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pronounced. Gleason score is generally higher in PZ tumors and found to be 
correlated to MVD by some [34, 35], but no correlation was found between GS and 
microvascular parameters in either of our studies. In the present study GS was 
comparable between TZ tumors and PZ tumors, and included Gleason grade 4 
pattems in both zonal tumors.
The so-called TZ-look, which comprises well differentiated glands of variable 
size with clear to pale pink columnar cells, is regarded as typical for TZ tumors [8]. 
Although this is not completely specific and can be focally present in up to 25% of 
PZ tumors, a predominant TZ-look is seen in 49% of TZ tumors and in only 4% of PZ 
tumors [3]. This TZ-look is considered to be more typical for Gleason grade pattem 1 
and 2, grades being almost exclusively found in the TZ zone [6, 8, 31], than for 
pattem 3, in which the cells usually have less and darker staining cytoplasm and 
larger nuclei with more prominent nucleoli [8], This histomorphological low grade 
appearance is sustained by the findings of lower proliferation rates for TZ tumors as 
compared to volume matched PZ tumors [11, 13].
At the molecular level, few studies have specifïcally investigated differences at 
the level of the zonal origin of prostate cancer. Older studies have reported a higher 
incidence of aneuploidy [36, 37] and numerical chromosomal aberrations[38] in PZ 
tumors, but this was not supported at the allelic level [39]. Although TZ and PZ 
tumors seem to share similar molecular aberrations, TZ tumors are reported to have 
these in lower frequency. The TMPRSS2-ERG gene, present in 43-50% of prostate 
cancers, is described in TZ tumors, but in a significantly lower frequency, ranging 
from 0 -17% [39, 40], and correlated to larger tumor volume. The same is reported for 
PTEN deletions [41].
No unequivocal precursor lesion has been identified for TZ tumors [42], in 
contrast to PZ tumors, which are highly associated with Prostatic Intraepithelial 
Neoplasia (PIN)) which shows comparable histomorphological and cytogenetic 
changes as PZ tumors, as well as an increased MVD [43]. This may indicate 
differences in pathogenesis and oncogenetic pathways. Further genetic research has to 
solve these questions.
In conclusion, different from PZ tumors, in which all microvascular parameters 
showed an almost twofold increase, no consistent increase in any microvascular 
parameter, MVD, MVP or MVA, was found in TZ tumors, as compared to normal TZ 
and PZ prostatic tissue, as well as to benign nodular prostatic hyperplasia, in which 
vascular parameters were increased. No differences were found between normal PZ 




Correlation between Dynamic Contrast 
Enhanced-MRI and Quantitative Microvascularity 
Parameters in Organ Confined Prostate Cancer
Comelis G. van Niekerk, MD1, Jeroen A.W.M. van der Laak, PhD1,
Thomas Hambroek, MD, PhD2, Henk-Jan Huisman, PhD2, J. Alfred Witjes, MD, 
PhD3, Jelle O. Barentsz, MD, PhD2, Christina A. Hulsbergen-van de Kaa, MD, PhD1




Objectives: To correlate pharmacokinetic parameters of 3T Dynamic Contrast 
Enhanced (DCE-)MRI, with histopathological microvascular parameters in organ 
confined prostate cancer.
Methods: Parameters were analysed of 18 patients with unilateral peripheral zone 
(pT2a) tumours who underwent DCE-MRI prior to radical prostatectomy without 
neo-adjuvant therapy, using a pharmacokinetic two-compartment model. Parameters 
assessed were permeability surface area volume transfer constant (^ trans)) 
extravascular extracellular volume (Ve) and rate constant (K^). Blood and lymph 
vessels were visualized immunohistochemically and scanned. Parameters assessed 
include microvessel density (MVD), -area (MVA) and -perimeter (MVP), 
lymphvessel density (LVD), -area (LVA) and -perimeter (LVP).
Results: A significant negative correlation was found between age and £ trans and 
for tumour (r=-0.597, p=0.009; r=-0.669, p=0.002) and normal (r=-0.54, p=0.021; r=- 
0.46, p=0.055) tissue. No correlation exists between absolute values of microvascular 
parameters from histopathology and DCE-MRI. In contrast, the ratio between tumour 
and normal tissue (correcting for the variation of parameters in normal tissue) 
significantly correlates between Kep and MVD (r=0.61, p=0.007) and MVP (r=0.54, 
p=0.022). The lymphovascular parameters did not show correlations, except between 
LVA and Kep (r=-0.662, p=0.003).
Conclusion: Microvascular characteristics explain (partly) tumour visibility in DCE- 
MRI. DCE-MRI should take into account the inter-prostatic heterogeneity of 
microvasculature between patients.
Key Points:
• Normal prostate tissue shows strong heterogeneity in microvascularity.
• Peripheral Zone prostate cancer shows increased and less heterogeneous- 
microvascularity.
• Microvascular characteristics explain (partly) tumour visibility in DCE-MRI.
• DCE-MRI should take into account the inter-prostatic heterogeneity of 
microvasculature between patients.




DCE-MRI Dynamic Contrast Enhanced - Magnetic Resonance Imaging
H&E hematoxylin and eosin
Kep rate constant










Ve extravascular extracellular volume
99
Introduction
Diagnostic improvements in prostate cancer are aimed at early detection, localization 
and staging as well as possible prediction of tumour aggressiveness of prostate 
cancer. The most commonly used clinical parameters for assessing the probability of 
organ-confined disease include digital rectal examination, serum PSA level and 
Gleason grading after systematic needle biopsy series. Transrectal ultrasound can be 
helpful in guiding biopsies in patients suspected for prostate cancer. However, due to 
their random sampling, clinically important cancers may be overlooked. When 
correlated with radical prostatectomy (RP) specimens, Gleason grading obtained by 
TRUS-guided biopsy has been shown to underestimate tumour Gleason score in up to 
40% of cases [1]. Multi-parametric MR imaging, including T2-weighted imaging, 
dynamic contrast enhanced MRI (DCE-MRI) and diffiision weighted MRI have been 
shown to improve the localization and determination of aggressiveness of prostate 
cancer [2, 3], Subsequent MRI guided biopsies increase the detection rate of clinically 
significant prostate cancer [4, 5],
The pathophysiological basis of tumour visualization by DCE-MRI is still not 
fully understood [6], Several histopathological studies on microvessel density found a 
twofold increase in tumour vascularity in prostate cancer compared to normal prostate 
tissue [7-9]. Increase in vascular density may explain the success of DCE-MRI. As a 
result of the strong perfusion of both tumour and normal prostate, simple pre- and 
post-contrast MR images are inadequate to detect malignancies. DCE-MRI methods, 
utilizing high-temporal scanning following contrast agent administration, modelling 
of the signal-intensity vs. time curves as well as estimation of pharmacokinetic tracer 
parameters, have been shown to be of great additional value in prostate MR imaging 
[10, 11]. Enhancement of the DCE-MRI signal in tumour area depends not only on 
vascular density but also on blood flow, vascular permeability, interstitial- or 
extravascular- and extracellular volume, interstitial pressure, and fïnally on the back 
flow into the blood or lymphatic system [12], Although we showed previously that no 
differences exist in the overall lymph vasculature between tumour and normal 
peripheral zone, individual lymph vessel morphology was different in (peri)tumoural 
as compared to normal tissue [13],
Not all detected prostate cancers are clinically relevant; therefore much attention 
is given to prognostic indicators for potentially aggressive tumours. In this respect, 
several studies have shown a correlation between MVD and increased risk on 
recurrence and poorer overall survival in prostate cancer [14], Erbersdobler et al 
found a significant increase in MVD in peripheral zone tumours compared to
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transition zone tumours, which may coincide with the fact that transition zone (TZ) 
tumours are less aggressive than PZ tumours [15].
Aim of the present study is to increase our understanding of the 
pathophysiological basis of DCE-MRI tumour visualisation, by correlating both 
microvascular and lymphatics parameters assessed in histological sections with DCE- 
MRI signals. Understanding this relationship may facilitate interpretation of DCE- 
MRI signals.
Materials and methods 
Patients
In this retrospective study, 18 patients with biopsy-confirmed prostate cancer who 
underwent a DCE-MRI and a radical prostatectomy during 2006-2009 were included 
for analysis. Patients were only included if they had organ confined unilateral 
peripheral zone disease (pT2a) and no prior hormonal or radiation therapy. Serum 
PSA and patiënt age at time of radical prostatectomy were obtained from patiënt files.
MR imaging protocol
Prior to prostatectomy MR imaging was performed using a 3T MR scanner (Siemens 
Trio Tim, Erlangen, Germany) using an endorectal coil (Medrad, Pittsburgh, USA) 
and pelvic phased array coils for signal reception. The endorectal coil was inserted 
and filled with a 40-mL perfluorocarbon preparation (Fomblin; Solvay-Solexis, 
Milan, Italy). Peristalsis was suppressed with an intramuscular administration of 20- 
mg Butylscopolaminebromide (Buscopan; Boehringer-Ingelheim, Ingelheim, 
Germany) and 1 mg of glucagon (Glucagen; Nordisk, Gentofte, Denmark). The 
imaging protocol, after evaluation of correct endorectal coil position with fast 
gradiënt echo imaging, included the following sequences. First, high resolution T2- 
weighted turbo spin echo sequences were performed with an in-plane resolution of 
0.4x0.4 mm, repetition time (TR) 3250 ms/echo time (TE) 116 m; flip angle 120 
degree; 15-19 slices; 3-mm slice thickness; echo train length 15; 180x180 mm field 
of view and 448x448 matrix in axial, coronal, and sagittal planes, covering the 
prostate and seminal vesicles. Secondly, 3D Tl-weighted spoiled gradient-echo 
images (TR/TE 34/1.6 ms, 14-degree flip angle, 12 transverse partitions on a 3D slab, 
3-mm section thickness, 192-mm field of view, 128 xl28 matrix, Grappa parallel 
imaging factor 2) were acquired during an intravenous bolus injection of 15 ml of 
gadopentetatedimeglumine (Dotarem; Guerbet, Paris, France)—which was 
administered with a power injector (Spectris; Medrad) at 2.5 mL/s and followed by a
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15-mL saline flush (the same dose was given to all patients). With this sequence, a 3D 
volume with 12 partitions was acquired every 3 seconds during 120 seconds, with the 
same positioning angle and center as the transverse T2-w sequence, covering the 
entire prostate (Figure IA).
Figure 1: Different imaging modalities showing a single prostate containing a pT2a 
tumour. A. Transverse T2 -  weighted MR image using gadopentetate dimeglumine 
contrast agent and an endorectal coil. B. DCE-MRI Kep. C. DCE-MRI FÏram. D. DCE- 
MRI Ve. In B -  D, lines demarcate the border o f the tumour (T -  Tumour) and 
normal zone (N -Normal). E. Macroscopic image o f a transverse slice, with tumour 
outlined in black. The prostate has been color coded for easy recognition, red 
represents right and green represents left. F. Automatedpseudocolor-mapping image 
of MVD. G. Automated pseudocolor-mapping image of perimeter. H. Automated 
pseudocolor-mapping image o f area. In figures F  - H  the lines demarcate the border 
o f the tumour (T — Tumour)
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Before contrast injection, the sarne transverse 3D Tl-weighted gradiënt echo 
sequence (with the exception of a TR of 800ms) was used to obtain proton-density 
images, with identical positioning to allow calculation of the gadolinium chelate 
concentration curves. The dosage of contrast medium was not taken into 
consideration but arterial input function (AIF) correction was done. The AIF was 
estimated and it was compensated for, thus the effect of diverse dosages was taken 
into consideration.
MR imaging post-processing
Imaging analysis was performed on an in-house developed analytical software 
workstation that calculates DCE-MRI pharmacokinetic (PK) parameters. The 
estimated PK parameters describe a PK model with two compartments assuming 
permeability limited conditions (aka regular Tofts model) extended with a start of 
enhancement parameter [16,17]. The implementation was as follows. Tl-weigthed 
signal enhancement was converted to a tracer concentration using the proton density 
signal. A general arterial plasma concentration-time curve was assumed. For each 
voxel PK parameters were estimated by fitting the best PK model driven by the 
arterial input function. PK parameters estimated are Ve, Kep and Ktrans (=Ve x Kep), 
where Ve is an estimate of the extravascular extracellular volume (expressed as a 
percentage), A^ans is the volume transfer constant (1 per minute), Kep is the rate 
constant (1 per minute) between the extracellular extravascular space and the plasma 
space. The PK parameters can be color coded and rendered semi-transparently over 
T2- weighted images (Figures 1 B, C, D) or viewed independently [17, 18].
Pathology
All prostatectomy specimens were completely embedded, as described 
previously [19]. Specimens were cut into serial 4mm transverse slices perpendicular 
to the dorsal rectal surface. The slices were photographed with a CCD-camera (Figure 
1 E). Apical and basal slices were then sectioned sagitally. Depending on the size of 
the prostate, the remaining slices were divided in two or four parts in order to fit 
routine cassettes. The tumour margins were marked on hematoxylin and eosin (H&E) 
stained sections by an experienced urological pathologist (CAHK). Tumour was then 
outlined on the macroscopic photographs in order to reconstruct tumour extension and 
multifocality. For this study also a mirror image area of equal size compared to the 
tumour was marked in the contra lateral normal tissue (tissue without significant 
inflammation or prostatic intraepithelial neoplasia). The Gleason grade and score 
were determined using the 2005 ISUP Modifïed Gleason Grading System [20]. 
Tumour volume was determined by measuring the largest tumour diameter and the
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diameter perpendicular to the largest diameter in all tissue sections containing 
tumour. Section tumour area was calculated from these diameters by assuming 
elliptical tumour shape, was integrated over all sections and multiplied by the section 
thickness to arrive at the estimated tumour volume.
Immunohistochemistry
Immunohistochemistry was performed on sections serial to the H&E stained sections 
containing the marked regions to identify blood and lymphatic vessels. Vessels were 
stained as described previously [9], A mouse anti-human CD31 monoclonal antibody 
(Clone JC70A, DakoCytomation, Copenhagen, Denmark) was used as the primary 
antibody at a dilution of 1:10 for blood vessels. A mouse anti-human D2-40 
monoclonal antibody (DakoCytomation, Copenhagen, Denmark, Clone D2-40) was 
used as the primary antibody at a dilution of 1:200 to identify lymph vessels. The 
specimens were incubated ovemight at 4°C. Specimens were washed in phosphate 
bufferd saline (PBS) and incubated with PowerVision (Poly-Hrp-Anti Ms/Rb/RtlgG 
Biotin-free, Immunologie, The Netherlands) for 30 minutes. Specimens were washed 
in PBS for 10 minutes and subsequently incubated with Power-DAB (Immunologie, 
The Netherlands) for 5 minutes resulting in brown staining of vascular endothelium. 
Finally, specimens were washed in water, dehydrated and mounted with Quick-D 
(Klinipath, The Netherlands). Sections used for quantitative analysis were not 
counterstained.
Automated analysis of microvasculature and lymphatics
Automated analysis of prostate specimens was performed using a method described 
previously [9]. In brief, a transverse section through the prostate was scanned and 
respectively microvessels or lymphvessels were recognized automatically based on 
positive immunohistochemical staining. KS400 image analysis software (version 3.0, 
Carl Zeiss, Germany) was used for all measurements. Next, in local circular regions 
(1.2mm2 in size) the following parameters were calculated (relative to the region 
size): microvessel density (MVD (l/mm2))), area (MVA (|im2/mm2)), perimeter 
(MVP (firn/mm2)) and lymph vessel density (LVD (1/mm2)), area (LVA (|^m2/mm2)) 
and perimeter (LVP (|xm/mm2)). The region size was selected to comply with the 
resolution of DCE-MRI. From these calculated parameters, pseudocolor mappings 
were produced (Figure 1 F, G, H). Quantitative data were extracted from pseudocolor 
mappings in manually delineated regions comprising the tumour and contra lateral 
normal tissue. To reduce the effect of region size, the region in normal prostate tissue 
was drawn with size and shape comparable to the tumour area. For every manually
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defined region, the median (p50) and 75th percentile (p75) were calculated for all 
parameters defined above.
Annotation of MRI data
Reconstructed whole-mount step-section histology tumour maps were used to identify 
the step-section with the biggest diameter in tumour dimensions. This step-section 
was used for correlation and measurement. Histopathology step-sections and MR 
imaging planes were made perpendicular to the dorsal surface of the prostate and of 
similar thickness (3-4mm). Using features on T2-weighted MR imaging, each H&E 
section was visually matched to a corresponding T2w image on the basis of the 
relative position of the ejaculatory ducts to the urethra, the dimension of the prostate, 
any identifiable benign prostatic hyperplasia nodule, and the approximate distance 
from the apex. To be considered a match, a focus of carcinoma must be at the same 
anterior or posterior half of the prostate and must be at the same superior to inferior 
level of the prostate and anatomical landmarks. For this slice, the corresponding Tl-w 
pre-contrast image was chosen and a region-of-interest (ROI) drawn on this image, 
corresponding to tumour location and size (Figure 1 B, C, D). A second ROI was 
drawn in the contra-lateral peripheral zone, representing a mirror ROI to tumour, 
regarding size and location. This matched the ROI used in the pathology analysis of 
normal tissue. For each ROI, following pharmacokinetic modeling, the DCE-MRI 
software then automatically extracted the pharmacokinetic features (A*ans: Kep and 
Ve) for the tumour and normal ROI. These quantitative values from DCE-MRI were 
then correlated to the pathology determined quantitative vascular features.
Statistical Analysis
Two approaches for comparing histological and DCE-MRI parameters were used. 
Next to using absolute values determined by microscopie analysis and DCE-MRI, the 
ratio obtained by dividing the tumour values by the corresponding normal tissue 
values was studied. The latter is less influenced by inter-patient prostatic variation. 
For all calculated parameters, the median value and 75* percentile (p75) were 
calculated for each prostate. The p75 gives information on the higher vascularized 
areas, and is therefore better comparable to the hot spots of parameters than the 
median value. Comparison between pathology and MRI were performed using 
Spearman’s rho correlation coëfficiënt. Difference between normal and tumour was 
studied using Wilcoxon signed ranks test. All statistics were performed using SPSS 
software (SPSS Inc, Chicago, II, USA). All probabilities from statistical tests are 
based on two-sided testing, significance being defined as p<0.05.
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Results
Patiënt characteristics are shown in Table 1. Mean patiënt age was 58.5 years (range 
48 -  69 years) with mean preoperative PSA of 7.4 ng/ml (range: 2.1 -  12.6 ng/ml). 
Tumours had volumes ranging from 0.3 -  4.8 cm3 (mean 1.6 cm3). The Gleason grade 
ranged from 2 - 5  (mean 3.3) with mean Gleason score 6.5 (range 5 -  9).
Table 1: Clinicopathological data o f 18 unilateral peripheral zone adenocarcinomas 
confined to the prostate (pT2a)














Consistent with our previous fïndings, a significant increase in vascular parameters 
MVD, MVA, and MVP was found in tumour as compared to normal prostate in the 
peripheral zone (Table 2) (p<0.001 for all parameters for both median and p75) [9], In 
contrast, the lymphatic vasculature showed no differences between tumour and 
normal peripheral zone, which is also in accordance with our previously published 
data (Table 2) [13],
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Table 2: Parameters values o f assessment o f histology and DCE-MRI; shown are 
median and p75 (represen ative o f the higher vascularized areas)
Normal Tumor Ratio
Mean (Std. deviation) Mean (Std. deviation) Mean (Std. deviation)
Median values
MVD 71.5 (34.1) 113 (26.2) 2.00 (1.08)
MVA 1.58 (0.84) 2.34 (0.96) 1.86 (1.00)
MVP 4.84 (2.89) 7.55 (2.38) 1.99 (1.08)
LVD 5.09 (2.55) 5.05 (1.72) 1.09 (0.35)
LVA 0.43 (0.36) 0.31 (0.11) 0.96 (0.49)
LVP 0.57 (0.28) 0.51 (0.13) 1.04 (0.49)
Kep 5.64 (1.89) 6.93 (1.92) 1.27 (0.25)
ĵ trans 0.10 (0.06) 0.17 (0.08) 1.81 (0.63)
Ve 1.78 (0.68) 2.34 (0.72) 1.36 (0.31)
P75 values
MVD 91.4 (37.9) 142 (30.7) 1.82 (0.86)
MVA 2.20 (1.05) 3.14 (1.23) 1.66 (0.72)
MVP 6.22 (2.84) 9.44 (2.93) 1.77 (0.78)
LVD 7.94 (3.79) 8.34 (2.94) 1.15 (0.38)
LVA 0.88 (0.61) 0.68 (0.30) 1 .0 0 (0.63)
LVP 0.98 (0.38) 0.90 (0.22) 1 .0 0 (0.41)
K ep 6.62 (2.07) 8.60 (2.60) 1.35 (0.36)
j^trans 0.13 (0.07) 0.22 (0.12) 1.83 (0.66)
Ve 2.01 (0.73) 2.57 (0.82) 1.32 (0.34)
Histopathological microvascular parameters showed large heterogeneity for normal 
prostatic tissue between patients (Figure 2) as well as within the same patiënt 
(illustrated in Figure 3). A correlation was found between histopathological 
parameters in normal and tumour tissue for MVD (r=0.48, p=.045), MVP (r=0.71, 
p=0.001; see Figure 4) and MVA (r=0.74, p=0.001). Clearly, characteristics of 
tumour vascularity depend on those in normal prostate, prompting for study of the 
ratio between tumour and normal prostate tissue parameters. Comparing the 
histopathological lymph vessel parameters in tumour and normal tissue between 
patients, there was only a significant correlation for LVD (r=0.53, p=0.024), but not 
for LVA or LVP.
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Figure 2: The figure illustrates the variation in normal tissue between patients for  
microvessel density; each circle represents an individual case











Spread of vessel density in normal prostate tissue (M VD 1/mm2).
Figure 3: An illustration o f intra-prostatic variation o f microvascularity between A, 
B. normal prostate tissue in the same prostate and C. prostate tumour (H&E stained; 
xlOO). D. automated mapping o f MVD (1/mm2)  for this prostate with tumour outlined 
in black
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Figure 4: The figure shows a significant correlation between microvessel perimeter 
(MVP) (/an) o f tumour and MVP (fjm) o f normal tissue (r = 0.709, p  = 0.001)
MVP (nm ) Normal prostate
As for microvasculature, also for the DCE-MRI pharmacokinetic parameters an 
increase in tumour as compared to normal prostate was observed for the 18 patients 
analysed (p<=0.001 for median and p75 values of K4™", KeP, and Ve). Comparing the 
absolute values of the histopathological parameters (MVA, MVD, MVP) with those 
of DCE-MRI (Kep, Klrans> Ve), no correlation was found (Table 3 upper part). 
Interestingly, using the ratio of the values between tumour and normal tissue, a 
significant correlation was found between Kep and the histopathological parameters 
MVD (r=0.61; p=0.007) and MVP (r=0.54; p=0.022) (Table 3 lower part and Fig. 5 
and Fig. 6). Comparable results were found for both median and p75 values. For 
lymph vessel parameters, the absolute tumour data showed only a significant negative 
correlation between LVA and Kep (r=-0.66; p=0.003), but not for the other parameters 
(Table 3 and Fig 7). No correlation was found for the (tumour-normal) ratio data 
(Table 3).
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Table 3: Correlation (ratio) o f histopathologic microvessel and lymph vessel 
parameters, with DCE-MRI pharmacokinetic parameters for the absolute tumour 
values (A) and the ratio (B) between Tumour and Normal tissue (p50). Correlation is 






MVD 0.069 -0.004 -0.027
MVA -0.030 0.12 0.15
MVP 0.003 0.10 0.083
LVD 0.030 0.076 0.030
LVA -0.66** -0.40 0.076
LVP -0.45 -0.24 0.14
Ratio tumor vs normal tissue
MVD 0.61** 0.36 -0.18
MVA 0.32 0.22 -0.007
MVP 0.54* 0.32 -0.12
LVD 0.098 0.20 0.29
LVA -0.046 -0.096 0.024
LVP 0.076 0.059 0.22
Figure 5: The graph shows a significant correlation between median (p50) MVD and 
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Figure 6: The graph shows a significant correlation between median MVP and Kep 
expressed as ratios o f normal to tumour tissue (r = 0.53, p  = 0.05
MVP (median, ratio tumour vs normal)
Figure 7: The graph shows a significant correlation between median L VA (%) and 
Kep (min1), r = -0.66, p  = 0.01
LVA (median over tumour area)
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No consistent correlation was found between histopathological microvascular 
parameters and age, preoperative PSA, tumour volume or Gleason score. However, a 
significant negative correlation was found between age and MRI parameters (K^ and 
£trans-j fQr tumour (r=_o.60, p=0.009; r=-0.67, p=0.002) and less significantly for 
normal tissue (r=-0.54, p=0.021; r=-0.46, p=0.055).
Discussion
In this study histological parameters of microvascularity were compared with DCE- 
MRI pharmacokinetic parameters to improve our understanding of the contribution of 
different microvascular features to contrast enhancement in DCE-MRI. DCE-MRI 
has been shown to be of great additional value in localization of prostate cancer. 
Preliminaiy results suggest that this type of functional imaging may also enable 
evaluation of biologie aggressiveness of prostate cancer [21, 22], In the present study 
a previously described microvascular quantification method for pathology [9] and an 
open pharmacokinetic two-compartment model for DCE-MRI [17] were used to 
correlate the different histopathological microvascular and MRI imaging parameters. 
A significant correlation was found between the MRI parameter Kep and pathology 
parameters MVD and MVP. This helps to understand the rationale for the success of 
in vivo MR imaging. The increased vascularity (MVD) provides increased inflow of 
contrast. The increased microvessel perimeter (MVP) provides increased permeability 
surface area. Kcp has formerly been described by Tofts et al. as the exchange rate 
constant between the extravascular extracellular space (Ve) and plasma space [17], 
Thus the correlation found between and MVD and MVP is well grounded seeing 
that Kep depends on both perfusion and vascular permeability.
It was expected that not only Kep but also K*™* would show similar correlation 
with MVD and MVP. Both parameters are rate constants for the transfer of 
Gadolinium-DTPA between intravascular and the extravascular extracellular 
compartment (Ve). This exchange process depends on microvascular factors like 
blood flow (MVA), number of bloodvessels (MVD), permeability surface area 
(MVP) and tissue factors like interstitial pressure, which depends on cellular density, 
chemical composition and functional lymphatic drainage. As K0-™8 is dependent on 
Kep and Ve (K^^KspX Ve), high K^ areas are seen especially when Ve is low as is 
the case in areas of high tumour cellular density. On the other hand, K03™ allows only 
areas to be seen with high Kep and high Ve. This shows that Kep is a sensitive 
parameter.
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The correlation between bloodvessel histopathological parameters with 
pharmacokinetic DCE-MRI parameters in this group of organ confined prostate 
cancer was shown by using the tumour-normal ratio values, but was not shown for 
absolute values. The lack of correlation between absolute values is explained by the 
fact that a large inter-patient variation exists for both normal and malignant regions. 
By using ratios we corrected for this inter-patient variability and found a higher, 
significant, correlation between histopathological microvascular parameters and 
DCE-MRI. This was further supported by the observation, that when tumour blood 
vessels were compared with normal blood vessels between patients, a significant 
statistical correlation (p<0.05) was found for MVD, MVP and MVA [9], This has 
important implications for the radiological interpretation of absolute pharmacokinetic 
DCE-MRI maps. Absolute values between patients for both tumour and normal tissue 
also show a large variability. Therefore, a better tumour -  normal discrimination is 
obtained when using pharmacokinetic parameter ratios for tumour-normal as well 
[23]. In this study, using absolute values, we also found a significant negative 
correlation between age and Kep and l f ans in tumour tissue, as well as in normal 
tissue, although the significance for K ev was borderline for normal tissue. This can 
possibly be explained by age-related factors like a decline in cardiac output and 
increase in atherosclerotic vascular changes [24]. These are related to changes in 
blood flow. This indicates that age plays an important role in prostate imaging using 
DCE-MRI, and it must be realized that vascular variables could change with age. 
There was no correlation shown for age and histopathological microvessel parameters 
in this study and a previous one [9], This could be due to the fact that 
histopathological parameters measure indiscriminately all microvessels, functional or 
not, while DCE-MRI measures only functional microvessels, and is more likely to be 
influenced by diminished cardiac output and atherosclerosis affected arterial inflow.
Only a few previous studies have studied the correlation between 
histopathological microvascular parameters and DCE-MRI. Schlemmer et al. showed 
that the MVD and MVA were increased in tumour and correlated to Kep (in their 
study called K21) [22], They only correlated absolute values. The current study could 
not replicate their findings. Important differences to their study were that we chose a 
more objective and therefore less biased method in quantifïcation of vessel 
parameters. Schlemmer et al. used the hot spot quantifïcation method and we used a 
previous described automated quantifïcation method [9]. Furthermore, despite having 
a slightly smaller population size, our population was more homogenous in 
composition i.e. we only measured patients with relatively small single sided stage 
pT2a tumours. In contrast their study included patients with locally advanced and 
more aggressive disease.
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In another study assessing the correlation of dynamic contrast MRI with prostate 
vascularity, Franiel et al. found a weak correlation between blood volume and MVD 
(p=0.014) but a lack of correlation between blood volume and its histopathologic 
counterpart MVA [25].They hypothesiscd that this lack of correlation or only poor 
correlation between the pharmacokinetic MR parameters and histologie parameters 
could be because of the heterogeneous vascularisation of both normal prostate tissue 
and prostate cancer. This agrees with our findings. Franiel et al. however, used a low 
molecular weight contrast agent to estimate blood volume parameters. Our analysis 
was done by a completely different method using exchange rate constants (K1™, K^, 
and Ve) and therefore not comparable to their study. The exchange rate constants 
have a more complex basis, as they are a fiinction of blood flow and surface 
penneability (which in turn is affected by vessel surface area). Schlemmer et al. and 
Franiel et al. compared only the absolute values for the microvascular parameters and 
did not consider interpatient variability by using ratios between tumour and normal 
tissue.
Until now, the Gleason grading system is the most powerful and widely utilized 
system to predict tumour aggressiveness. There are, however, also indications that 
MVD independently correlate with disease progression [26]. Therefore, the 
correlation we found between Kep and MVD may indicate that the determination of 
Kep might not only add to the localization accuracy of DCE-MRI, but also suggest an 
additional role in tumour aggressiveness and prognostication.
To the best of our knowledge we are the fïrst to compare lymph vessel parameters 
with DCE-MRI parameters. Absolute tumour data from lymph vessel area (LVA) 
showed a significant negative correlation with Ktp, but showed no significant 
correlation for the same variables using the ratio’s, possibly because there are so few 
lymphvessels with less inter-patient variability. We propose the increasing interstitial 
pressure causes the lymphatics in the tumour to become non-functional (area becomes 
smaller). Contrast medium is then removed by veins and functional peritumoural 
lymphatics. It has been shown that peritumoural lymphatics serve as major conduits 
for metastases, thus proof of their functionality [27].
In conclusion, in early stage prostate cancer a significant correlation was found 
between Kep and MVD and MVP, using the ratio of the values between normal and 
cancer tissue. Imaging data should take into account the inter-prostatic heterogeneity 
of microvasculature between patients. Using a normalized prostate reference method 
for arterial input estimation may therefore aid our interpretation of imaging findings. 
The relative increased microvascularity in prostate cancer enables a contrast enhanced 
MRI-technique for visualization of prostate cancer in the peripheral zone.
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The complex dynamics of fluid (blood, lymph) transport through human tissues, and 
alterations therein caused by malignant processes form the basis of success of DCE- 
MRI. Understanding these dynamics will consequently aid the interpretation of DCE- 
MRI signals, and may clarify why certain tumors are more easily detected than others. 
This thesis was specifïcally aimed at measuring microvessels and their parameters; 
microvessel density (MVD), microvessel area (MVA) and microvessel perimeter 
(MVP) in prostate cancer and the contra lateral normal prostate tissue of different 
zones of the prostate and finding anomalies and comparisons. These were correlated 
with the images found when scanning the prostate with DCE-MRI and the chosen 
pharmacokinetic parameters; rate constant (K^p), transfer constant (Ktraas) and 
extravascular extracellular volume (Ve). We do this in order to validate images found 
on DCE-MRI through angiogenesis, so ultimately extensive invasive sampling will 
not be necessary to detect and stage prostate cancer, in addition this technique would 
lend itself to early diagnosis and appropriate intervention. This thesis does not deal 
with the associated prognosis or the different prognostic factors associated with 
prostate cancer.
In this thesis the application of a repeatable computerized whole slide quantifïcation 
method is used, which has been chosen in order to purge interobserver variation, be 
able to factor in biologie variation, eliminate hot-spot bias and reduce the effect of 
intratumoral heterogeneity. The MVD quantifïcation according to Weidner and the 
Chalkey procedure as described by Fox do not fully satisfy the basic concepts of 
stereology [1] and therefore may lead to biased results [2,3]. The automated counting 
of microvessels is preferred over manual counting because it greatly reduces time 
spent when the complete tumor is scanned and there is greater accuracy and 
objectivity, the possibility of visual inspection and relocation of the measured field is 
possible afterwards [4,5],
This thesis shows that a consistent significant increase in vascular parameters MVD, 
MVA and MVP was found in tumour versus contra lateral normal prostate in the 
peripheral zone (PZ). This is in concordance with previous studies [6-9], Bigler et al 
found on average a two-fold increase in MVD in 15 cases of prostate cancer 
compared to normal prostate tissue. MVD was averaged over 5 randomly selected 
regions. Kaygusuz et al also found a two-fold increase in MVD, measured as the 
mean of three hot spots. This figure is slightly higher than the 1.8-fold increase (1.7- 
fold for 75* percentile) found in the present study. Bigler et al studied in general
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larger tumours with a higher stage (50% > pT3) compared to the present study. 
Kaygusuz compared between tumour and benign hyperplasia, which may exhibit 
microvascular properties differing from those in normal peripheral zone. The present 
study is focused on small (pT2) tumours, as these are most difficult to visualize in 
vivo and compared with the contra lateral normal prostate tissue. In contrast, only a
1.47-fold increase was found for MVD assessed in hot spots in the study of Eberhard 
et al [9], which is markedly smaller than the 1.7-fold increase observed in the present 
study. Eberhard does not give information about tumour volume, stage or zonal origin 
of normal tissue. The 75* percentile, which was referred to, provides information on 
the higher vascularised areas and is therefore better comparable to the hot spot than 
the mean value. The heterogeneity, expressed in the coëfficiënt of variability (CV) of 
vascular parameters MVD, MVA and MVP was decreased in tumour as compared to 
normal tissue in the present study. The same observation may be derived from data 
published by Bigler [7]. An explanation for this phenomenon may be that the strongly 
increased levels of angiogenic factors (e.g. VEGF) [6] result in a ‘saturation’ of the 
vascular bed. It was argued that vessel density in tumours may exceed the metabolic 
requirements [10]. Probably, this process may lead to a more uniform, strongly 
overvascularised tissue. This shows that especially the increase in MVP, which may 
be regarded as a relative measure for the 3D vascular diffusion surface, may 
contribute to increased uptake of radiological contrast agents in prostate cancer as 
compared to normal prostate tissue.
In this thesis no correlation was found between microvascular parameters and 
Gleason score. Conflicting results conceming this issue have been published in the 
literature. Arakawa et al [11] and Bettencourt et al [12] found a significantly 
increased MVD with increasing Gleason score. MVD counts fail on multivariate 
analysis as an independent prognostic factor [11,13-15]. Moreover, the predictive 
accuracy of the multivariable base model including age, PSA, stage, Gleason score, 
and margin status was not meaningfully improved by the addition of MVD [13].
The lymphatic system develops parallel to the blood vascular system and therefore 
may be regarded as complementary to the microvasculature. Very few studies have 
been aimed at recognizing the lymphatic vessels due to the difïïculty of distinguishing 
them from blood vessels [16]. In this thesis we used D2-40 which, has been proven an 
excellent marker for lymphatic endothelium [17], it fulfïlled all our requirements and 
we where able to apply it in our computerized whole slide quantification method.
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Contradictory to most other studies, in this thesis no differences were found between 
tumor and normal tissue regarding the extent of the lymphatic bed as expressed in the 
lymph vessel density (LVD). In addition to the gross, overall lymphatic density, we 
also assessed the geometry of individual lymph vessel profïles. Significantly smaller 
(area, perimeter and diameter) profïles were observed intratumorally as compared to 
tumor periphery as compared to normal prostate. The degree of variation in these 
parameters was identical in all compartments.
Although previous studies agree on the intratumoral LVD being significantly smaller 
than the peritumoral LVD, inconsistent results were found conceming normal prostate 
tissue. Normal prostate was found to possess increased [18-20], similar [21] or even 
decreased [22] LVD compared to tumor tissue. Differences between such findings 
may often be attributed to variations in methodology. No previous studies 
quantitatively assessed geometry of individual lymph vessels. However, it was 
described that lymph vessels are either small and collapsed or large with open lumina 
in normal prostate [21,22], In contrast, presence of only small collapsed vessels in 
tumor tissue was observed [21,22], These observations match our observation of 
tumor lymphatics being smaller compared to normal tissue. Interestingly, Kim found 
mainly large lympahtics in the peritumoral region whereas Zeng describes small, 
collapsed vessels in this region. In the present study peritumoral lymph vessels seem 
to resemble normal lymphatics, matching Zengs’ observation. From these results, we 
hypothesize that overall there is no difference in LVD between tumor and normal 
tissue. Results from previous studies may be influenced by selection criteria for 
normal and tumor tissue, and by criteria for selecting measurement regions within 
these compartments. A growing tumor mass is obliged to induce lymphangiogenesis 
to remain at the same overall LVD, as observed in the present study. Otherwise a 
tumor devoid of lymphatics would result. This is supported by the fact that prostate 
tumors show upregulation of VEGF-C [23], Also, the fact that in the present study 
intratumoral lymphatics were significantly smaller compared to peritumoral and 
normal lymphatics supports this view. We disagree with Trojan, who argued that 
destruction of lymphatics takes place within prostate tumors [24].
These results indicate that contrast enhancement and late washout of Gadolinium- 
DTPA in DCE-MRI are not caused by alterations in the number of tumor lymphatics. 
The intratumoral vessels tend to collapse especially those without supportive stromal 
structures leading to impaired function [25], The limited literature on this subject 
provides a unified stance, describing non-functional lymphatics within the tumor and 
functional lymphatics peritumoral, which serve as major conduits for metastasis [26],
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Transition zone (TZ) tumors should be considered separately from PZ cancer as it has 
a more indolent course, higher cure rate and overall better prognosis [27, 28]. In this 
thesis data indicate a tendency (not reaching statistical significance) towards an 
overall increase in the extent of the vascular bed in TZ tumor as compared to normal 
TZ, with a lower variability of the vascular parameters. Variability over patients 
however is large; with patients showing both increased and decreased vascularity in 
the tumor. In contrast, the vascular bed in glandular BPH compared to normal TZ 
shows an overall smaller but more consistent increase in vascular parameters, with 
decrease in the variability of these parameters. For individual patients, this results in 
glandular BPH (if present) being mostly hyper-vascularized compared to normal TZ, 
with the TZ tumor possessing either increased or decreased numbers of bloodvessels 
compared to both normal TZ and glandular BPH regions. To the best of our 
knowledge, in this thesis this is the first study, which compares microvascularity in 
TZ tumors with normal TZ prostatic tissue. The lack of a consistent increase in 
microvascularity in TZ tumors is in contrast with the increase in microvascular 
parameters (MVD, MVP and MVA), which was observed in PZ tumors, both in the 
present study and in our previous study on organ confïned PZ tumors [29], We 
previously found up to an 1.7-fold increase for these parameters in PZ tumors, where 
other studies have reported a 1.47- to 2.4-fold increase in MVD for prostate 
cancer [6-9], However, in contrast to the present study, in these studies no distinction 
in zonal origin of the tumors was made. Our fïndings are in agreement with those of 
Erbersdobler et al [28], who did compare the MVD of volume matched TZ tumors 
and PZ tumors, and found a signifïcantly lower mean MVD in TZ tumors than in PZ 
tumors.
On patiënt level a strong positive correlation was observed between PZ tumor and 
normal PZ for all vascular parameters. A similar, be it weaker, correlation was seen 
for TZ tumor versus normal TZ. These data may indicate a stronger and more 
consistent role for pro-angiogenic factors in PZ tumors compared to TZ tumors. 
However, only few biological studies have been performed related to the zonal origin 
of prostate cancer and thus far no differences in VEGF levels have been reported [30]. 
The lack of a consistent increase in the microvascularity in TZ tumors as compared to 
PZ tumors, which could not be explained by differences in the basic microvasculature 
of the two zones, favors the theory that intrinsic biological differences exists between 
the two zonal tumor types. These are, at least partly, responsible for different clinical 
behavior. There are several arguments to support this theory. From a 
histomorphological point of view, most studies reported a lower mean Gleason Score 
(GS) in TZ tumors [31-34], especially when matched for tumor volume [28], although
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this was not found by all investigators. In this thesis no correlation was found 
between microvascular parameters and tumour volume. The median tumor volume 
was even larger in the TZ tumors than in the PZ tumors, which makes the difference 
in microvascular parameters between the tumors even more pronounced. Gleason 
score is generally higher in PZ tumors and found to be correlated to MVD by some 
[11, 12], but no correlation was found between GS and microvascular parameters in 
either of our studies. In the present study GS was comparable between TZ tumors and 
PZ tumors, and included Gleason grade 4 pattems in both zonal tumors.
The so-called TZ-look, which comprises well differentiated glands of variable size 
with clear to pale pink columnar cells, is regarded as typical for TZ tumors [35], 
Although this is not completely specific and can be focally present in up to 25% of 
PZ tumors, a predominant TZ-look is seen in 49% of TZ tumors and in only 4% of PZ 
tumors [36]. This TZ-look is considered to be more typical for Gleason grade pattem
1 and 2, grades being almost exclusively found in the TZ zone [32,35, 37,], than for 
pattem 3, in which the cells usually have less and darker staining cytoplasm and 
larger nuclei with more prominent nucleoli [35], This histomorphological low grade 
appearance is sustained by the fmdings of lower proliferation rates for TZ tumors as 
compared to volume matched PZ tumors [28, 30]. At the molecular level, few studies 
have specifïcally investigated differences at the
level of the zonal origin of prostate cancer. Older studies have reported a higher 
incidence of aneuploidy [28, 38] and numerical chromosomal aberrations [39] in PZ 
tumors, but this was not supported at the allelic level [40]. Although TZ and PZ 
tumors seem to share similar molecular aberrations, TZ tumors are reported to have 
these in lower frequency. The TMPRSS2-ERG gene, present in 43-50% of prostate 
cancers, is described in TZ tumors, but in a significantly lower frequency, ranging 
from 0 -17% [41, 42], and correlated to larger tumor volume. The same is reported for 
PTEN deletions [43].
The differences observed in this thesis between the vascular characteristics of TZ and 
PZ tumors may well reflect differences observed with respect to the detectability of 
prostate tumor on DCE-MRI. Whereas PZ tumors are mostly detectable because of a 
strong increase in signal (probably reflecting increased perfusion of the tumor), 
detection rates of TZ tumors are lower. TZ tumors may either show an increase or 
decrease of the DCE-MRI signal compared to its background, which consists of BPH, 
normal TZ tissue or both. BPH nodules in the TZ are strongly enhanced in DCE-MRI 
to the same or even a higher degree than TZ tumors [43]. This is in agreement with 
the results of the present study, in which PZ tumors always showed an increase in
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vascular parameters, whereas TZ tumors showed large heterogeneity. Presence of 
BPH in this compartment of the prostate hampers detection even further.
DCE-MRI has been shown to be of great additional value in localization of prostate 
cancer. Preliminary results suggest that this type of functional imaging may also 
enable evaluation of biologie aggressiveness of prostate cancer [44, 45]. In this thesis 
a previously described microvascular quantification method for pathology [29] and an 
open pharmacokinetic two-compartment model for DCE-MRI [46] were used to 
correlate the different histopathological microvascular and MRI imaging parameters. 
A significant correlation was found between the MRI parameter Kep and pathology 
parameters MVD and MVP. This helps to understand the rationale for the success of 
in vivo MR imaging. The increased vascularity (MVD) provides increased inflow of 
contrast. The increased microvessel perimeter (MVP) provides increased permeability 
surface area. Kep has formerly been described by Tofts et al. as the exchange rate 
constant between the extravascular extracellular space (Ve) and plasma space [46]. 
Thus the correlation found between Kep and MVD and MVP is well grounded seeing 
that Ktp depends on both perfusion and vascular permeability. It was expected that not 
only Kep but also Kimns would show similar correlation with MVD and MVP. Both 
parameters are rate constants for the transfer of Gadolinium-DTPA between 
intravascular and the extravascular extracellular compartment (Ve). This exchange 
process depends on microvascular factors like blood flow (MVA), number of 
bloodvessels (MVD), permeability surface area (MVP) and tissue factors like 
interstitial pressure, which depends on cellular density, chemical composition and 
functional lymphatic drainage. As K0™1 is dependant on KeP and Ve (Ktrans=K<:pX Ve), 
high areas are seen especially when Ve is low as is the case in areas of high tumor 
cellular density. On the other hand, Ktrans allows only areas to be seen with high KeP 
and high Ve. This shows that KeP is a sensitive parameter.
The correlation between bloodvessel histopathological parameters with 
pharmacokinetic DCE-MRI parameters in this group of organ confined prostate 
cancer was shown by using the tumor-normal ratio values, but was not shown for 
absolute values. The lack of correlation between absolute values is explained, by the 
fact that a large inter-patient variation exists for both normal and malignant regions. 
By using ratios we corrected for this inter-patient variability and found a higher, 
significant, correlation between histopathological microvascular parameters and 
DCE-MRI. This was further supported by the observation, that when tumor blood 
vessels were compared with normal blood vessels between patients, a significant 
statistical correlation (p<0.05) was found for MVD, MVP and MVA [29]. This has
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important implications for the radiological interpretation of absolute pharmacokinetic 
DCE-MRI maps. Absolute values between patients for both tumour and normal tissue 
also show a large variability. Therefore, a better tumour -  normal discrimination is 
obtained when using pharmacokinetic parameter ratios for tumour-normal as 
well [47], In this thesis, using absolute values, we also found a significant negative 
correlation between age and Kep and K?ans in tumour tissue, as well as in normal 
tissue, although the signifïcance for Kep was borderline for normal tissue. This can 
possibly be explained by age-related factors like a decline in cardiac output and 
increase in atherosclerotic vascular changes [48], These are related to changes in 
blood flow. This indicates that age plays an important role in prostate imaging using 
DCE-MRI, and it must be realized that vascular variables could change with age. 
There was no correlation shown for age and histopathological microvessel parameters 
in this study and a previous one [29], This could be due to the fact that 
histopathological parameters measure indiscriminately all microvessels, functional or 
not, while DCE-MRI measures only functional microvessels, and is more likely to be 
influenced by diminished cardiac output and atherosclerosis affected arterial inflow.
Only a few previous studies have studied the correlation between histopathological 
microvascular parameters and DCE-MRI. Schlemmer et al. showed that the MVD and 
MVA were increased in tumor and correlated to Kep (in their study called K21) [49]. 
They only correlated absolute values. The current study could not replicate their 
findings. Important differences to their study were that we chose a more objective and 
therefore less biased method in quantifïcation of vessel parameters. Schlemmer et al. 
used the hot spot quantifïcation method and we used a previous described automated 
quantifïcation method [29]. Furthermore, despite having a slightly smaller population 
size, our population was more homogenous in composition i.e. we only measured 
patients with relatively small single sided stage pT2a tumors. In contrast their study 
included patients with locally advanced and more aggressive disease.
In another study assessing the correlation of dynamic contrast MRI with prostate 
vascularity, Franiel et al. found a weak correlation between blood volume and MVD 
(p=0.014) but a lack of correlation between blood volume and its histopathologic 
counterpart MVA [50].They hypothesised that this lack of correlation or only poor 
correlation between the pharmacokinetic MR parameters and histologie parameters 
could be because of the heterogeneous vascularisation of both normal prostate tissue 
and prostate cancer. This agrees with our findings. Franiel et al. however, used a low 
molecular weight contrast agent to estimate blood volume parameters. Our analysis 
was done by a completely different method using exchange rate constants (Ktrans, Kcp,
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and Ve) and therefore not comparable to their study. The exchange rate constants 
have a more complex basis, as they are a function of blood flow and surface 
permeability (which in turn is affected by vessel surface area). Schlemmer et al. and 
Franiel et al. compared only the absolute values for the microvascular parameters and 
did not consider interpatient variability by using ratios between tumor and normal 
tissue.
To the best of our knowledge we are the fïrst to compare lymph vessel parameters 
with DCE-MRI parameters. Absolute tumor data from lymph vessel area (LVA) 
showed a significant negative correlation with Kep, but showed no significant 
correlation for the same variables using the ratio’s, póssibly because there are so few 
lymphvessels with less inter-patient variability. We propose the increasing interstitial 
pressure causes the lymphatics in the tumor to become non-functional (area becomes 
smaller). Contrast medium is then removed by veins and functional peritumoral 
lymphatics. It has been shown that peritumoral lymphatics serve as major conduits for 
metastases, thus proof of their functionality [26],
Dynamic contrast enhanced MRI (DCE-MRI) is a promising technique by using 
physiological and pharmacokinetic modeling in probing microvascular properties of 
angiogenesis. Using the ratio of the values between normal and cancer tissue imaging 
data should take into account the inter-prostatic heterogeneity of microvasculature 
between patients. By using a normalized prostate reference method for arterial input 
estimation may therefore assist in our interpretation of imaging fïndings. The relative 
increased microvascularity in prostate cancer enables a contrast enhanced MRI- 
technique for visualization of prostate cancer in the peripheral zone.
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In summary a Histological and DCE-MRI description of findings in this thesis.
Histological description DCE-MRI description
Normal Peripheral zone 
(NoPZ)
Normal heterogeneous distribution 
of microvessels
No/decreased enhancement in the 
Kep parameter
Tumor Peripheral zone 
(TuPZ)
Overall an almost twofold 
increase in microvascularity 
compared to normal peripheral 
zone and microvessels are more 
homogenous.
Enhancement in the KeP 
parameter which has cirumscript 
aspect
Normal Transition zone 
(NoTZ)
Heterogeneous distribution of 
microvessels with significant 
increase in MVD and MVP 
compared to NPZ
* Enhancement is more 
compared to NoPZ
Transition zone Tumor 
(TuTZ)
Heterogeneous distribution of 
microvessels with increased 
microvessel area
* Circumscript aspect of 
increased enhancement
Benign Prostatic Hyperplasia 
(BPH)
Vessels in BPH are uniformly 
larger than in NTZ, and maintains 
a homogenous character
* Circumscript aspects of 
increased enhancement
* Not yet validated thus no comment can be issued as to which PK parameter would best correlate with 
histologie findings.
Limitations to this Thesis:
In all studies condueted a relatively small study population was used; this was due to 
the strict inclusion criteria. More studies with larger patiënt populations and different 
inclusion criteria should be done to further refine the DCE-MRI method.
The transition zone microvascular parameters ought to be correlated with transition 
zone DCE-MRI pharmacokinetic parameters, subsequently angiogenesis and DCE- 
MRI can be better evaluated as a whole. There is still much research to be done on 
this subject.
Future perspectives:
More studies containing a larger study population and specifying a uniform method 
for microvessel parameter measurement and DCE-MRI pharmacokinetic parameter 
measurement in different zones of the prostate should be done. DCE-MRI will not be 
the sole answer for locating and accurately diagnosing prostate cancer. To ultimately
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choose for less-invasive diagnostic tools of prostate cancer, a multiparamaetric 
approach should be preferred, combining morphological, functional, perfusion, 
difEusion and metabolic imaging since a tumor consist out of far more than blood 
vessels. It is an inhomogeneous mass of tissue with a wide variety of chemical 
imbalances, genetic aberrations, hormones, and self-regulating growth factors.
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In this thesis it is shown that the application of a computerized whole slide 
quantification method produces repeatable results in measuring microvascular 
parameters like microvascular density, microvascular area and microvascular 
perimeter and can therefore be universally implemented for bloodvessel and 
lympvessel measurements. With this method we were able to compare objectively 
measurements taken in histological cut sections with measurements taken from 
pharmacokinetic enhancement pattems on DCE-MRI. It was determined 
neoangiogenesis plays a role in the enhancement pattem in DCE-MRI, thus providing 
proof for the use of DCE-MRI as a diagnostic tooi in prostate cancer.
Chapter 2
Contrast enhanced imaging enables powerful, non-invasive diagnostics, important for 
detection and staging of early prostate cancer. The uptake of contrast agent is 
increased in prostate cancer as compared to normal prostate tissue. To reveal the 
underlying physiological mechanisms, quantification of vascular tissue components in 
pathology specimens may yield important information. The aim of this study was to 
investigate whether microvascularity is increased in prostate confined cancer (pT2). 
Radical prostatectomy specimens of 26 patients were selected for organ confined 
peripheral zone tumours which were restricted to one side of the prostate. 
Microvessels were visualized by immunohistochemistry against CD31. Specimens 
were scanned using a computer controlled microscope and scanning stage and vessels 
were recognized automatically. Pseudocolour mappings were produced showing 
number of vascular profiles (MVD), vascular area (MVA) and perimeter (MVP) in an 
overview of the entire prostate transection. MVD is a common measure for 
vascularity, whereas MVA represents the 3D vascular volume and MVP the perfused 
surface area. The mean, coëfficiënt of variation and 75th percentile of these 
parameters were calculated automatically in manually indicated areas, consisting of 
the entire tumor area and the corresponding normal area in the contra lateral side of 
the prostate. The mappings clearly indicate areas of increased vascularity in prostate 
transections. In peripheral zone tumour tissue an increase was found compared to 
normal peripheral zone tissue of 81%, 49% and 62% for mean MVD, mean MVA and 
mean MVP, respectively (pO.OOl for all comparisons). In contrast, the heterogeneity 
in tumour vasculature was signifïcantly decreased as compared to normal prostate 
(pO.OOl). Characteristics of microvasculature deviated signifïcantly in pT2 
peripheral zone prostate tumor as compared to normal peripheral zone tissue.
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Chapter 3
The objective of this study was to analyze the characteristics of lymphatic vasculature 
in normal and (peri)tumoral prostate tissue, applying accurate and objective 
quantifïcation techniques based on digital image analysis. Radical prostatectomy 
specimens of 27 patients were selected containing organ confined peripheral zone 
tumors, which were restricted to one side of the prostate (pT2a). Lymph vessels were 
visualized by immunohistochemistry with D2-40, a specifïc antibody for 
lymphvessels. Lymphatic vessel density, perimeter, and area were assessed over the 
entire tumor and corresponding contralateral normal tissue. Also, morphology (area, 
perimeter, and diameter) of individual lymph vessels were measured in (peri)tumoral 
and normal tissue. No differences were found in the overall lymph vasculature 
between tumor and normal peripheral zone. However, the area, perimeter, and 
diameter of individual lymph vessel profiles were significantly decreased in 
(peri)tumoral as compared to normal tissue. No differences were seen for these 
parameters between peritumoral and tumoral area. Comparing the coëfficiënt of 
variation between compartments (normal, (peri)tumoral), no differences were 
observed for any parameter. Although differences exist between the morphology of 
individual lymph vessels in tumor versus normal tissue, the overall vascular bed 
(number and summed area and perimeter of lymphatics per area unit tissue) is 
unaffected in tumor. Peritumoral lymphatics resemble lymphatics in tumor tissue 
rather than normal lymphatics.
Chapter 4
The objective of this study was comparison of characteristics of the microvasculature 
in transition zone (TZ) tumor and benign nodular hyperplasia (BPH) with normal 
prostatic TZ, applying accurate and objective quantifïcation based on digital image 
analysis. Results of this study may increase understanding of prostate dynamic 
contrast enhanced (DCE) MRI analysis. Radical prostatectomy specimens of 28 
patients containing TZ tumors ranging from pT2 -  pT4 were used. In 11 patients a 
concomitant peripheral zone (PZ) tumor was present. Microvessels were visualized 
by CD31 immunohistochemistry. Specimens were scanned using a computer 
controlled microscope with automatic recognition of microvessels. Pseudocolor maps 
were produced displaying microvessel density, perimeter, and area of an entire 
prostate transection. Mean, 75th percentile (p75) and coëfficiënt of variation (CV) 
were calculated automatically in manually indicated areas of the tumor and 
corresponding contralateral normal tissue, and BPH. Large variability was seen in TZ 
tumor microvascular parameters, indicating presence of patients having both hypo- 
and hypervascularised tumors compared to normal TZ. In contrast, areas of BPH
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showed a more consistent increase in vascular parameters, with decreased CV. 
Analysis of PZ tumors confirmed the results of our previous study, with mean and 
p75 of all vascular parameters being significantly increased and a decrease in CV. No 
correlation was found for clinicopathological parameters and microvascular 
parameters.
Microvasculature of transition zone tumors showed increased heterogeneity 
compared to BPH and peripheral zone tumors, possibly explaining the difïïculty of 
TZ tumor detection on DCE-MRI.
Chapter 5
In this study we investigated the pathophysiologigal enhancement of organ confined 
prostate cancer in 3T Dynamic Contrast Enhanced MR Imaging (DCE-MRI). The 
pharmacokinetic enhancement parameters: permeability surface area volume transfer 
constant (K_mms), extravascular extracellular volume (Ve) and rate constant (Kep) were 
correlated to the histopathological microvascular parameters: microvessel density 
(MVD), -area (MVA) and -perimeter (MVP), as well as lymphvessel density (LVD), - 
area (LVA) and -perimeter (LVP). Eighteen patients with unilateral peripheral zone 
(pT2a) tumors were selected who underwent DCE-MRI prior to radical prostatectomy 
(RP) without neo-adjuvant therapy. 3T DCE-MRI was performed using an endorectal 
coil and gadolinium-chelate contrast agent to visualize tissue vascularity. DCE-MRI 
data were analyzed using a pharmacokinetic two-compartment model. In the RP 
specimen’s blood and lymph vessels were visualized using CD31 and D2-40 antibody 
respectively. One whole axial prostate slice was scanned using a computer-controlled 
microscope and scanning stage. Vessels were recognized, and parameters were 
determined automatically. A significant negative correlation was found between age 
and KiT*ns and Kep for both tumor ( r=-0.597, p=0.009; r=-0.669, p=0.002) and slightly 
less significant for normal tissue ( r=-0.541, p=0.021; r=-0.46, p=0.055). Comparing 
the absolute values from microvascular parameters as measured by histopathology 
(MVA, MVD, MVP) and DCE-MRI (Kep, Z*rans, Ve) no correlation was found. In 
contrast to this, when using the ratio between tumor and normal tissue, which corrects 
for the variation of the different parameters in normal tissue between patients, a 
significant correlation was found between and MVD (r=0.613, p=0.007) and 
MVP ( r=0.537, p=0.022), for both the p50 (median) and p75 values. Comparing 
normal and tumor tissue between patients, a statistical significant correlation was 
found for MVD (r=0.478, p=0.045), MVP (r=0.709, p=0.001) and MVA ( r=0.736 
p=0.001). The lymphovascular parameters showed only a significant negative 
correlation between LVA and Kep (r=-0.662, p=0.003) using the absolute tumor data, 
but not for the other parameters nor for the ratio’s.
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In organ confined prostate cancer a significant correlation was found between Kep and 
MVD and MVP, using the ratio of the values between normal and cancer tissue. The 
interpretation of imaging data, therefore, should take into account the inter-prostatic 
heterogeneity of microvasculature between patients. The relative increased 
microvascularity in prostate cancer enables a contrast enhanced MRI-technique for 
visualization of prostate cancer in the peripheral zone.
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Samenvatting (Nederlands/Dutch)
In dit proefschrift wordt aangetoond dat het gebruik van een geautomatiseerde “whole 
slide quantification” methode reproduceerbare resultaten oplevert voor de meting van 
microvasculaire parameters, zoals microvasculaire dichtheid, microvasculaire 
oppervlaktes en microvasculaire perimeters, en dus universeel geïmplementeerd kan 
worden voor bloedvat- en lymfevatmetingen. Met deze methode is het daardoor 
mogelijk om een objectieve vergelijking te maken tussen metingen verricht in 
histologische coupes en metingen uit het farmacokinetische aankleuringsprofiel van 
Dynamische Contrast Enhanced MRI (DCE-MRI). Hierdoor werd vastgesteld, dat 
neo-angiogenese in prostaatkanker een rol speelt bij de toegenomen contrast 
aankleuring op DCE-MRI, hetgeen derhalve het gebruik van DCE-MRI als 
diagnostische methode voor het aantonen van prostaatkanker verklaart en 
rechtvaardigt.
Hoofdstuk 2
Contrast Enhanced Imaging geeft een goede mogelijkheid tot niet-invasieve 
diagnostiek, belangrijk voor de detectie en stagering van vroege prostaatkanker. De 
opname van contrastmiddel is verhoogt in prostaatkanker in vergelijking met normaal 
prostaatweefsel. Voor het ontrafelen van de mogelijke onderliggende fysiologische 
mechanismen van deze contrastverhoging, kan kwantificering van vasculaire 
componenten in pathologie specimens belangrijke informatie opleveren. Het doel van 
deze studie was om te onderzoeken of microvascularisatie verhoogd is in 
orgaanbeperkte prostaatkanker (pT2). Hiertoe werden radicale prostatectomie (RP) 
preparaten van 26 patiënten geselecteerd met eenzijdige en orgaanbeperkte, perifere 
zone tumoren. Bloedvaten werden gevisualiseerd door middel van 
immuunhistochemische aankleuring met een antilichaam gericht tegen CD31. De 
coupes werden vervolgens gescand met een computer gestuurde microscoop met 
scanfase en de bloedvaten werden automatisch herkend. Door middel van artificiële 
kleurbeelden werden vasculaire profielen in kaart gebracht, microvatdichtheid 
(MVD), -oppervlak (MVA), en -perimeter (MVP), in gereconstrueerde complete 
dwarsdoorsneden van een prostaat.
MVD is een algemene maat voor de vasculariteit of te wel het aantal bloedvaten per 
mm , MVA vertegenwoordigt het 3D microvasculaire bloedvatvolume en MVP geeft 
het perfusie oppervlak. Het gemiddelde, de variatiecoëfïïciënt en de 75ste percentiel 
van deze parameters werden automatisch berekend in manueel gemarkeerde gebieden 
bestaande uit het gehele tumorgebied en een qua grootte en locatie overeenkomend 
normaal gebied in de contralaterale zijde van de prostaat. De artificiële kleurkaarten
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toonden gebieden met duidelijk verhoogde vascularisatie in prostaat secties. In 
vergelijking met de normale prostaat perifere zone werden voor perifere zone 
prostaatkanker verhoogde waardes gevonden met een factor 81%, 49% en 62% voor 
gemiddelde MVD, MVA en MVP respectievelijk (p<0.001 voor alle vergelijkingen). 
In contrast hiermee, was de heterogeniteit in de tumor vasculatuur significant 
afgenomen in vergelijking met het normale prostaatweefsel (p<0.001). De kenmerken 
van de microvasculatuur in pT2 perifere zone prostaattumoren waren dus significant 
verschillend van die in normale perifere zone prostaatweefsel.
Hoofdstuk 3
Het doel van deze stadie was om vervolgens de eigenschappen van de lymfe 
vasculatuur in normaal en (peri)tumoraal prostaat weefsel te bestuderen met boven 
beschreven accurate en objectieve kwantatieve technieken gebaseerd op digitale beeld 
analyse. Radicale prostatectomie specimens van 27 patiënten met orgaanbeperkte, 
eenzijdige, perifere zone tumoren werden geselecteerd (pT2a). Lymfevaten werden 
gevisualiseerd door immuunhistochemische aankleuring met D2-40, een antilichaam 
dat specifiek lymfevaten aankleurt. Lym fvatdichtheid, -perimeter en -oppervlak 
werden bepaald in de gehele tumor en in het overeenkomstige contralaterale normale 
weefsel. De morfologie (oppervlak, perimeter en diameter) van individuele 
lymfevaten werd ook bepaald in de (peri)tumorale gebieden en in het normale 
weefsel. Er werden geen significante verschillen gevonden in de algehele lymfe 
vasculatuur tussen tumor en normale perifere zone, maar het vasculaire oppervlak, 
perimeter en diameter van individuele lymfevaten was significant verlaagd in 
(peri)tumorale gebieden vergeleken met het normale weefsel. Er werden geen 
verschillen waargenomen voor deze parameters tussen peritumorale en tumor 
gebieden. Vergelijking van de variatiecoëfïïciënten leverde voor geen van de 
parameters verschillen op tussen de compartimenten (normaal, (peri)tumoraal). 
Hoewel er dus wel verschillen zijn in de morfologie van individuele lymfevaten in 
tumor vs. normaal weefsel, blijkt het algehele lymfevatbed (aantal en som van 
oppervlak en perimeter van de lymfvaten per mm2 weefsel) onveranderd in de tumor. 
Peritumorale lymfevaten lijken meer op de lymfevaten in tumorweefsel dan op 
normale lymfvaten.
Hoofdstuk 4
Het doel van deze studie was om de eigenschappen van de microvasculatuur in de 
transitie zone (TZ) tumor, in benigne nodulaire hyperplasie (BPH) en in normale 
transitie zone met elkaar te vergelijken door middel van deze objectieve, 
kwantificeerbare, digitale beeld analyse. De resultaten van deze studie kunnen ons
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begrip van DCE-MRI analyse in TZ tumoren verbeteren. Radicale prostatectomie 
specimens van 28 patiënten met TZ tumoren stadium pT2 -  pT4 werden 
geïncludeerd. In 11 patiënten was er ook een perifere zone (PZ) tumor aanwezig. 
Microbloedvaten werden gevisualiseerd door middel van CD31 immuunhistochemie. 
Coupes werden gescand door een computer gestuurde microscoop met automatische 
herkenning van microvaten. Artificiële kleurenbeelden werden gemaakt voor de 
microvatdichtheid, -perimeter en -oppervlak van een hele prostaat dwarsdoorsnede. 
Het gemiddelde, de 75ste percentiel (p75) en de variatiecoëfficiënt (CV) werden 
automatisch berekend in de manueel geselecteerde gebieden van tumor en 
overeenkomstige contralaterale normale TZ, en BPH. Er werd een grote variabiliteit 
(hoge CV) aangetoond in de microvasculaire parameters van de TZ tumoren, waarbij 
patiënten zowel hypo- als hypergevasculariseerde tumoren hadden in vergelijking met 
normale TZ. In contrast daarmee, toonden gebieden met BPH een meer consistente 
verhoging in vasculaire parameters met juist een verlaagde CV. Analyse van de 11 PZ 
tumoren bevestigde de resultaten van de vorige studie (Hoofdstuk 2) met een 
gemiddelde en p75 die voor alle vasculaire parameters significant verhoogd was ten 
opzichte van normale PZ, en juist een verlaging van de CV. Er werd geen correlatie 
gevonden voor de clinicopathologische parameters en de microvasculaire parameters. 
De eigenschappen van de microvasculatuur van de transitie zone tumoren met een 
verhoogde heterogeniteit in vergelijking met BPH en perifere zone tumoren, kan een 
verklaring geven voor het feit dat TZ tumoren vaak zo moeilijk te detecteren zijn op 
DCE-MRI.
Hoofdstuk 5
In deze studie werden bij orgaanbeperkt prostaatkanker de pathofysiologische 
aankleuringsmechanismen in 3 Tesla DCE-MRI onderzocht. De farmacokinetische 
(PK) parameters, waardoor versterkte aankleuring bepaald wordt - de oppervlakte 
permeabiliteitvolume transfer constante (^ trans), het extravasculaire extracellulaire 
volume (Ve), en de snelheidsconstante (K^) - werden gecorreleerd aan de 
histopathologische microvasculaire parameters: microbloedvatdichtheid (MVD), - 
oppervlak (MVA) en -perimeter (MVP), alsook aan de lymfevatdichtheid (LVD), - 
oppervlak (LVA) en -perimeter (LVP). Daartoe werden 18 patiënten met unilaterale 
perifere zone (pT2a) tumoren geselecteerd, bij wie een 3T DCE-MRI was gemaakt 
voorafgaand aan de radicale prostatectomie (RP) en die geen neo-adjuvante 
behandeling hadden gekregen. 3T DCE-MRI was uitgevoerd met gebruik van een 
endorectale spoel en gadolinium-chelate contrast middel om de weefsel vasculariteit 
te visualiseren. DCE-MRI data werd geanalyseerd met behulp van een 
farmacokinetische twee-compartiment model. In de RP specimens werden bloed- en
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lymfevaten gevisualiseerd door middel van CD31 en D2-40 antilichamen 
respectievelijk. Eén hele axiale prostaat doorsnede werd gescand door een computer 
gestuurde microscoop met scanfase. Vaten en werden automatisch herkend en 
parameters automatisch berekend. Er werd een significante negatieve correlatie 
gevonden tussen leeftijd van de patiënt en de ^ trans en Kep voor de tumor (r= -0.597, 
p=0.009; r -0.669, p=0.002) en iets minder significant voor het normale weefsel (r= - 
0.541, p0.021; r= -0.46, p=0.055). Vergelijking van de absolute waardes van 
histopathologische microvasculaire parameters (MVD, MVA, MVP) en DCE-MRI 
parameters (Kep, Â rans, Ve) leverde geen significante correlaties op. Echter, wanneer 
de ratio tussen tumor en normaal weefsel werd gebruikt, hetgeen corrigeert voor de 
variatie in de parameters voor normaal weefsel tussen patiënten, werd wel een 
significante correlatie gevonden tussen Kep en MVD (r=0.613, p=0.007) en MVP ( 
r=0.537, p=0.022), voor zowel de p50 (mediaan) als de p75. Vergelijking van 
normaal en tumor weefsel tussen patiënten gaf een significante onderlinge correlatie 
voor MVD (r=0.478, p=0.045), MVP (r=0.709, p=0.001) en MVA ( r=0.736 
p=0.001). Voor de lymfe microvasculaire parameters werd slechts een significante 
negatieve correlatie gevonden voor LVA en Kep (r=-0.662, p=0.003) voor de absolute 
tumor data, maar niet voor de ander parameters en ook niet voor de ratio’s.
In orgaanbeperkte prostaatkanker werd een significante correlatie gevonden 
tussen en MVD en MVP door gebruik te maken van de ratio van de gevonden 
waarden in normaal en kanker weefsel. Dit betekent dat bij de beoordeling van de 
beeldvormende diagnostiek data er rekening moet worden gehouden met de 
heterogeniteit in de prostaatmicrovasculatuur tussen patiënten onderling. De relatief 
verhoogde microvasculariteit in prostaatkanker maakt het mogelijk om perifere zone 
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